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 1
1 INTRODUCTION 
 
Botulism is a non-febrile highly fatal disease of man and animals caused by 
neurotoxins of Clostridium botulinum. It is characterized by partial or complete flaccid 
paralysis of the muscles of locomotion, mastication and deglutition due to inhibition of 
the release of the neurotransmitter acetylcholine by botulinum neurotoxins at 
cholinergic nerve endings (Kriek and Odendaal, 1994). Botulism occurs sporadically, 
but in intensively farmed animals, it is responsible for high mortalities (Smart et al., 
1983; Abbitt et al., 1984; Trueman, 1992). Animal botulism can be a public health 
problem, since humans can be intoxicated by ingestion of contaminated meat. Minute 
quantities acquired by ingestion, inhalation or by absorption through the eye or a 
break in the skin can cause profound intoxication and death in humans (CDC, 1998). 
 
C. botulinum encompasses a heterogeneous group of obligate anaerobic, spore-
forming, Gram-positive rods that produces the most potent biologic toxin known 
(Rocke, 1993). It produces seven neurotoxins that are pharmacologically similar, but 
serologically distinct from each other and designated as types A through G (Rocke, 
1993). The bacterium is almost ubiquitous and is found in soils and organic matter 
worldwide. Eventhough C. botulinum is nearly ubiquitous in the environment and in 
the flora of herbivores; it may not always be toxic, perhaps helping to explain the 
sporadic nature of the outbreaks (Galey, 2001). C. botulinum is occasionally present 
in the animal gut (Ricketts and Greet, 1984) and can be an opportunist due to gut 
stasis (Hunter et al., 1999). 
 
Several forms of botulism in both man and animals were described (Smith and 
Sugiyama, 1988; CDC, 1998), but in general it is either due to intake of the 
preformed toxin (classical form) or the toxin is formed inside the animal body after 
colonization by C. botulinum (toxico-infectious form). The classical form of botulism is 
usually due to ingestion of a food contaminated with botulinum neurotoxins (food-
borne botulism), while the toxico-infectious (TI) form is usually due to proliferation of 
C. botulinum in an existing wound (wound botulism) or in the gut (visceral botulism, 
Böhnel et al., 2001). The TI form mainly occurs in human infants (infant botulism) or 
foals (shaker foal syndrome) and rarely in adult humans or animals (Arnon et al., 
1978; Bartlett, 1986).      
 
 2
Equine grass sickness (EGS), a disease of horses, ponies and donkeys, was first 
recognized in the northeast of Scotland in 1907 (Tocher et al., 1923), then spread to 
the other parts of Britain, Europe and some other parts in the world (McCarthy et al., 
2001), but is still of unknown aetiology. It was suspected to be a toxico-infectious 
form of botulism due to some similarities between its clinical picture and that of the 
botulism. The disease is characterized clinically by signs of autonomic dysfunction of 
the gastrointestinal (GI) tract due to severe and extensive damage in neurons of the 
autonomic (mainly enteric) nervous system (Pollin and Griffiths, 1992).  Many 
evidences have been produced indicating that C. botulinum is most likely the cause 
(Tocher et al., 1923; Hunter and Poxton, 1998; Poxton et al., 1998; Hunter et al., 
1999; Böhnel et al., 2003; McCarthy et al., 2004b). However, due to the sporadic 
nature of the disease, other scientists see that C. botulinum is ubiquitous and it is 
unlikely to be linked with the disease (Collier et al., 2001). The link of C. botulinum 
with GS should be confirmed by the detection of C. botulinum and/or its toxin in GS 
samples and their prevalence be significantly more than in control samples. 
However, the more definitive linkage is achieved when the disease is experimentally 
caused. 
 
Due to the severity of botulism and the great hazard it causes to both man and 
animals, the diagnostics of C. botulinum and its toxin are still insufficient (Robinson 
and Nahata, 2003; Gessler and Böhnel, 2003); and probably the disease is 
substantially under diagnosed (CDC, 1998; Böhnel et al., 2001). A presumptive 
diagnosis is made on the basis of the history, clinical signs, negative post-mortem 
examination and exclusion of similar diseases. A definitive diagnosis depends on: 1) 
the demonstration of botulinum toxin in the feed or source of intoxication, serum, GI 
contents or wound of a patient; 2) demonstration of bacterial forms of C. botulinum in 
GI contents, internal organs or feed; or 3) detection of antibody response to C. 
botulinum in recovered patients (Smith and Sugiyama, 1988). The diagnosis of EGS, 
unlike botulism, can be confirmed by histopathological examination either of the 
sympathetic ganglia and/or ileal tissue at post mortem or of the ileal biopsies 
obtained at laparotomy from living animals (Scholes et al., 1993). Laboratory 
diagnostics include the conventional culture methods to isolate the organism, mouse 
bioassay, molecular and immunological typing, and some other methods. C. 
botulinum is difficult to isolate (Smith and Sugiyama, 1988). It is extremely fastidious, 
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strict anaerobic, there is no selective medium for all its groups, and it can lose its 
toxicity during the isolation process. Isolation of C. botulinum is especially important 
for vaccine production, as C. botulinum strains are locality specific. The major 
definitive and standard test used to identify botulism is the toxin neutralization using 
the mouse bioassay. The bioassay is especially important in cases where the 
specimen contains only detectable toxin. The case in which PCR is useless and 
ELISA may be less sensitive. However, it is not suitable for examination of test 
samples containing other lethal substances (Dezfulian and Bartlett, 1985) and is of 
insufficient sensitivity relative to the extreme sensitivity of the horse (Galey et al., 
2000). Horses are suggested to be 1-10,000 times more sensitive than mice (Kinde 
et al., 1991). Recently, sensitive immunoassays such as enzyme-linked 
immunosorbent assay (ELISA) (Ferreira et al., 2003) and polymerase chain reaction 
(PCR)-based methods (Szabo et al., 1994b) were developed for diagnosis of 
botulism. Immunoassays, unlike the mouse bioassay, can detect the toxin either in 
active or inactive form. However, ELISA methods are most often less sensitive than 
the mouse bioassay (Trueman et al., 1992). Several reports showed that PCR 
amplification is a reliable alternative to the standard bioassay method for identifying 
BoNT-producing clostridia (Szabo et al., 1994a and b: Fach et al., 1996). PCR is 
important if the specimen contains viable cells and no detectable toxin by the 
bioassay or immunoassay (Szabo et al., 1994a). Thus, combination of culture 
method, bioassay, immunoassay and PCR seems to be important for better 
diagnosis of botulism.  
 
Following the death of the thoroughbred racehorse, Dubai Millennium, from EGS, the 
Dubai Millennium Research Foundation (DMF) was set up with the intention of further 
investigating the hypothesis that equine grass sickness is caused by a toxico-
infection with C. botulinum and to better understand potentially trigger factors. The 
current study is a part of this project.  
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2 REVIEW OF THE LITERATURE 
2.1 Equine grass sickness  
 
2.1.1 Definition 
Equine grass sickness or equine dysautonomia (ED) is a disease of horses, ponies 
and donkeys of unknown aetiology, characterized clinically by signs of autonomic 
dysfunction of the GI  tract due to severe and extensive damage in neurons of the 
autonomic (mainly enteric) nervous system (Pollin and Griffiths, 1992). As its name 
indicates, it occurs almost exclusively in horses while at pasture and rarely reported 
in stabled animals (Gilmour, 1987). 
 
2.1.2 History and distribution 
Equine grass sickness was first identified in the northeast of Scotland at a military 
training camp at Barry in Angus near Dundee (McLaren, 1918; Spreull, 1922; Tocher 
et al., 1923; Greig, 1924) in 1907 (Tocher et al., 1923), where about 100 army horses 
died because of the disease. The disease was then spread to the other parts of 
Scotland, England and Wales, which now have the highest incidence, but the 
disease is well recognized in Northern Europe, specially Sweden, Denmark, 
Germany and less in France, Belgium, Italy, Holland, Norway, Finland and 
Switzerland (Cottrell et al., 1999; McCarthy et al., 2001). In Austria, the first case of 
histologically confirmed grass sickness (GS) was only very recently reported 
(Wlaschitz and Url, 2004) in a four-year old pony mare. A single case confirmed 
histopathologically was reported in the Falklands (Woods and Gilmour, 1991). A 
condition in horses apparently similar to GS was described by OCHOA and STELLA 
DE VELANDIA (1978) in Columbia, and more laterally, in the USA and Colombia 
(Hedderson and Newton, 2004). Also GS was reported to occur in Australia (Stewart, 
1977). In addition, a grass sickness-like syndrome prevailing in Argentina and 
southern Chile, where it is known as ‘mal seco‘, was discovered in 1912 (Uzal and 
Robles, 1993), the same period of the first recognition of EGS. The syndrome, 
because of its typical epidemiology, clinical signs and histopathology to EGS, 
suggested being also EGS (Uzal and Robles, 1993; Hunter and Poxton, 2001; Araya 
et al., 2002).  
 
 5
2.1.3 Aetiology 
Despite the early recognition of the disease, in 1907, the aetiology is still unknown. 
Numerous epidemiological studies and laboratory investigations to all likely causative 
agents have been carried, but none is proved to be the cause. Different agents 
investigated are bacteria, effect of adverse weather conditions on grass (oxidative 
stress and excitotoxicity), mycotoxins, toxic plants, viruses, insect vectors, nutritional 
deficiencies, chemicals and metabolic upsets (Tocher, 1923; Anon, 1936; Greig, 
1942; Bartosz, 1997; Robb et al., 1997; Hunter and Poxton, 2001). However, the 
nature of the autonomic nervous system neuronal damage suggests that a type of a 
neurotoxin is involved (Griffiths et al., 1994). This suggestion was already confirmed 
by the experiment done by GILMOUR (1973b) and by POGSON et al. (1992). 
Potential neurotoxins proposed are toxins of C. botulinum group III (especially type 
C), mycotoxins (especially of Fusarium germinearium) and secondary metabolites of 
grasses (Bartosz, 1997; Robb et al., 1997; Cottrell et al., 1999).  
 
2.1.3.1  Suspected agents   
Bacteria. Bacteria are among the agents that were first suspected to be the cause of 
EGS. A bacterium morphologically and toxicologically resembling Bacillus botulinus 
(now C. botulinum) was first isolated from the GI tract of a case of EGS in 1919 and, 
subsequently from the spleens of a number of horses with GS (Tocher et al., 1923). 
However, TOCHER et al. (1923) stated that “any normal animal can swallow a large 
number of C. botulinum spores without any ill effect. There must be a predisposing 
cause to EGS“. They thought it likely to be gastric irritation. Thereafter, many eviden-
ces have been produced indicating that C. botulinum, especially type C is the most 
likely candidate (Miller, 1994; Poxton et al., 1997; Hunter and Poxton, 1998; Poxton 
et al., 1998; Hunter et al., 1999; Hunter and Poxton, 2001; Böhnel et al., 2003; 
McCarthy et al., 2004b). More details about the likelihood of C. botulinum to be the 
cause are shown below. C. perfringens type A enterotoxin has been detected in 
serum of suspected GS horses in Columbia that were not confirmed by 
histopathological examination (Ochoa and de Velandia, 1978). However, GILMOUR 
et al. (1981) found a negative serological association between cases of GS and C. 
perfringens type A in Scotland. The sera from acute and chronic cases of the disease 
failed to neutralise either crude or partially purified enterotoxin of C. perfringens. At 
an early stage of investigations a diplostreptococcus similar to that associated with 
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Borna disease was isolated from the CNS of an acute case of GS. However, when 
horses inoculated with this isolate intracranially, subcutaneously and intravenously 
remained normal. It was later concluded that this organism was without aetiological 
significance in GS (Greig, 1942).  
 
 Mycotoxins. A number of fungal species, including Fusarium germinearium are 
commonly found more prevalent in pastures where there have been confirmed cases 
of EGS than in other pastures (Doxey et al., 1991; Robb et al., 1997). Cultures of the 
species F. graminearium were specially found extremely toxic to neurons in vitro 
(John et al., 1997). Investigation of fungi isolated from the equine alimentary lumen 
did not identify any particular EGS-associated species, but did identify species with 
the potential to produce neurotoxins (Doxey et al., 1990). UZAL and ROBLES (1997) 
fed Fusarium cultures to four horses for four days; the animals showed signs of mild 
to moderate colic. Furthermore, F. germinearium mycotoxin is a severe 
gastrointestinal irritant and is immunosuppressive; it probably has its greatest effect 
on gut-associated lymphoid tissue (Pestka et al., 1987), whereby compromising 
mucosal immunity. This fungus could be a predisposing factor to C. botulinum 
(Collier et al., 2001). 
 
Secondary metabolites in grass and increased activity of nitridergic neurons. High 
incidences of EGS occur shortly after periods of cool, dry weather with irregular 
ground frosts (Doxey et al., 1991), conditions which alter plant metabolism and inhibit 
plant growth. It is established that plants in such conditions undergo oxidative stress 
and may have increased concentrations of secondary metabolites including various 
phenolics, nitrate, glutamate, aspartate, malonate, lipid peroxides, and reduced 
concentrations of antioxidants including ascorbate, thiols, alpha-tocopherol, beta-
carotene, superoxide dismutase, reduced glutathione, glutathione reductase and 
dehydroascorbate reductase (Draper, 1972; Taylor et al., 1972; Bartosz, 1997). It is 
possible that some of these secondary metabolites could induce neuronal death in 
EGS (Cottrell et al., 1999). Also, it has been suggested that grazing horses ingest 
high levels of these compounds which in turn can stimulate increased production of 
nitric oxide from nitridergic neurons within the autonomic nervous system, which can 
account for many of the clinical signs of ED (Cottrell et al., 1999).  
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Toxic plants. It is suggested that a toxic plant may be the cause, but no evidence has 
been shown (Robb et al., 1997). White clover due to its cyanide-producing properties 
was proposed and tested by TOCHER et al. (1923), who did an experiment to test 
the toxicity of alsike clover by let horses to feed on it for an entire season. No ill effect 
was observed. It was proposed that ingestion of highly cyanogenic wild white clover 
may be an important trigger factor for the disease because it inhibits GI motility and is 
microbiocidal. In addition, the cyanide content of clover varies with the growth cycle, 
thereby possibly explaining some of the seasonality of EGS (Hedderson and Newton, 
2004).  McGORUM et al. (2000) found that plants collected immediately after an 
outbreak of ED had reduced antioxidants and weak prooxidants activities when 
compared with control plants. Also, ED plants had significant increased concentration 
of fructose and low molecular weight phenolic compounds. They thought that these 
changes may contribute directly or indirectly to GS. 
 
Other agents suspected. An extensive survey of the insect populations failed to 
establish any relation with GS (Anon, 1936). GREIG (1942) took the view that a 
filterable virus was the most likely cause, but no evidence of association of the 
disease with any virus has been shown. Also, chemicals, nutritional deficiencies and 
metabolic upsets are suggested and examined, but showed no link with the disease. 
Moreover, frequent usage of anthelmintics (viz. ivermectin) is suspected to increase 
the risk of the disease (Wood et al., 1997), which might interfere with gut function in 
some way that increases the absorption of a neurotoxin (Milne, 1997), but this was 
not confirmed by WOOD et al. (1998). 
 
2.1.3.2 Why Clostridium botulinum is most likely the cause? 
Clostridia are normally found in the healthy colon, where their numbers are kept in 
check by other bacteria. However, when they establish themselves in the ileum they 
become formidable foes (Johnson, 2001). They digest fibre and produce medium 
length fatty acids that increase water absorption, causing hypertension and drying up 
the faeces, causing constipation (Johnson, 2001). C. botulinum can be an 
opportunist due to gut stasis (Collier et al., 2001).  
  
Many evidences have been produced indicated that C. botulinum is the most likely 
candidate (Tocher et al., 1923; Miller, 1994; Poxton et al., 1997; Hunter and Poxton, 
1998; Poxton et al., 1998; Hunter et al., 1999; Hunter and Poxton, 2001; Garrett  et 
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al., 2002; Böhnel et al., 2003; McCarthy et al., 2004b). Bacillus botulinus (now C. 
botulinum) was first isolated from the gut of a case of EGS in 1919 and also from the 
spleens of a number of horses with GS (Tocher et al., 1923). TOCHER et al. (1923) 
injected the toxin of his isolate (C. botulinum) subcutaneously in horses and it 
produced signs of acute GS. Also, a vaccination trials utilizing a toxin/antitoxin 
mixture, derived from known strains of B. botulinus (probably type B) involving over 
2000 horses on different farms were performed as randomised control trials (Tocher, 
1924). Half the horses on each farm were inoculated and the other half acted as 
controls. Two doses were given in spring in the first year of the study; this resulted in 
2.8 % mortality rate in vaccinated animals compared to 9.3 % in controls. Using a 
vaccine of a higher protective value in the second year, the mortality in controls was 
10 % compared to only 1.5 % in inoculated animals. Evidence has been produced for 
C. botulinum type C neurotoxin production in EGS cases (59 % of ileal contents, 47 
% of faecal samples) and unaffected control animals (7 % of ileal contents, 3 % of 
faecal samples) (Hunter and Poxton, 1998). Also, rising titres of specific systemic 
antibodies to surface antigens of C. novyi type A, a non-botulinum-toxin-producing 
species identical in cell surface composition to group III C. botulinum, and BoNT/C 
were detected in horses that had been in contact with EGS or that were grazing on 
land where GS had occurred frequently in the past compared to significantly lower 
levels of antibodies in horses with GS (Hunter and Poxton, 2001). This finding 
indicates that horses with low levels of systemic immunity to these antigens may be 
more susceptible. BoNT/C was also detected directly by ELISA in the ileum of 45 % 
(13/29) of horses with GS compared to 4 % (1/28) of controls, and in the faeces of 44 
% (20/45) of horses with GS compared to 4 % (3/77) of controls. The organism was 
detected indirectly by assay for BoNT/C by ELISA after enrichment in culture 
medium. C. botulinum type C was shown to be present in 48 % (14/29) of ileum 
samples and 44 % (20/45) of faecal samples from horses with GS, compared to 7% 
(2/27) of ileum samples and 8 % (6/72) of faecal samples from controls (Hunter et al., 
1999). From this study (Hunter et al., 1999), the BoNT/C was detected directly and/or 
after enrichment in the GI tract of horses with acute GS (74 %), subacute (67 %) and 
chronic (67 %) compared to 10 % in controls (Hunter and Poxton, 2001). HUNTER et 
al. (1999) have acknowledged that the association of C. botulinum type C with EGS 
may be a result of the stasis of the GI tract, but together with serological data (Hunter 
and Poxton, 2001) they hypothesized that the association is causal.  Also, recent 
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studies (McCarthy, 2002; McCarthy et al., 2004b) have shown that EGS cases have 
significant lower serum antibody titre to C. botulinum type C and its toxin than horses 
that either have been in contact with EGS affected horses or have grazed frequently 
affected pastures. Moreover, in a recent work to investigate two cases of confirmed 
EGS in a stud in South England (Böhnel et al., 2003), the results supported the 
hypothesis that GS in horses is a clinical form of botulism. Different types and type 
mixtures (A-E) of C. botulinum and BoNT were found. Test samples included grass, 
soil, compost (biofertilizer), faeces and tissues (from one case). The free BoNT was 
found for the first time in the growing grass as well as in anaerobic enrichment 
cultures. BoNT/C and D was demonstrated in one of the compost samples, and three 
contained toxigenic C. botulinum type A-D in mixed forms in enrichment cultures. In 
tissue samples, BoNT/C and D were detected in spleen, mid-jejunum and small 
colon; while the enrichment cultures showed toxicity only in the small colon (type D). 
HUNTER (http:/www.grasssickness.org.uk/research/milk_leonie_hunter.htm) 
reported that specific antibodies to C. botulinum type C were detected in both 
colostrum and milk of mares which had been in contact with GS. However, he found 
no significant difference between antibody levels in mares that had been in contact 
with GS and those had no contact. Unlike antibodies, the toxin was not detected in 
milk of cattle inspite of the high dose (175 ng/kg body weight) of BoNT/C injected 
(Moeller Jr. and Davis, 2001). A significant increase in the clostridia numbers in EGS 
cases compared to controls and isolation of 14 Clostridium species (including C. 
botulinum group III) from EGS cases compared to only one (C. bifermentans) from 
control animals was reported by GARRETT et al. (2002).  Also, GRIEß et al. (1996) 
has observed a prominent increase in numbers and types of clostridial cells in horses 
with typhlocolitis or colic compared to healthy horses. Only C. perfringens was 
isolated from healthy horses. 
 
C. botulinum neurotoxin type C is suspected for a number of reasons. BoNT/C has a 
unique neurotoxicity in that it is the only botulinum neurotoxin that can cause overt 
neuronal degeneration (Williamson et al., 1995). It is therefore possible that BoNT/C 
can cause damage to a wide range of neurons in vivo. C. botulinum type C produces 
three types of toxins: C1, C2 and C3 (Mauss et al., 1990; Hara-Ykama et al., 1994). 
BoNT/C1 inhibits the release of acetylcholine at cholinergic nerve terminals leading 
to flaccid paralysis. It prevents neurotransmitter release by specific proteolysis of 
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syntaxin (Schiavo et al., 1995) and SNAP-25 (Foran et al., 1996), which are 
synatosomal proteins that are involved in synaptic vesicle exocytosis. C2 and C3 
have ADP-ribosylating activity (Mauss et al., 1990; Hara-Ykama et al., 1994). C2 is 
known to inhibit neutrophil migration which could account for the characteristic 
absence of inflammatory reaction in EGS, and it is also known to enhance 
neurosecretory release and hypersecretion, a likely feature of EGS (Rocke, 1993; 
Cottrell et al., 1999). C3 can cause neuronal degeneration in vitro (Williamson and 
Neale, 1998) and hence it can account for the chromatolysis in EGS. All the three 
toxin types of C. botulinum type C might be involved in producing the typical 
pathology of EGS (Cottrell, 1999; Hunter et al., 1999). BoNT/C is severely toxic to 
mouse spinal cord neurons (Williamson and Neale, 1998) and rat hypocampal and 
cortical neurons (Osen-Sand et al., 1996) in culture. 
 
Moreover, C. botulinum is suspected due to the clinical similarities observed between 
EGS, human infantile botulism (Cottrell et al., 1999) and shaker foal syndrome, which 
are also toxico-infections by spores of C. botulinum, and forage poisoning in hoses, 
due to ingestion of preformed botulinum toxins. 
 
2.1.4 Epizootiology 
Equine grass sickness, as its name indicates, occurs almost exclusively in animals 
while at pasture and very rare in stabled animals (Greig, 1942; Scholes et al., 1993). 
It affects horses, ponies and donkeys. Grass sickness was also reported in a 
common zebra (Ashton et al., 1977). Dysautonomias similar to equine dysautonomia, 
which are also of unknown aetiology, were reported in dogs (Rochlitz and Bennett, 
1983), cats (Key and Gaskel, 1982), hares and rabbits (Whitwell, 1997). The 
neuropathology of the dysautonomias exhibited by these animals is reported to be 
remarkably similar (Pollin and Griffiths, 1992; Whitwell, 1997). WHITWELL (1997) 
stated that “it is not unrealistic to hypothesize that the dysautonomias in all these 
species could arise following exposure to the same or very similar neuronal insult“.  
 
Several risk factors that are associated with the disease were described. The 
epidemiological data showed that the disease is more prevalent during spring and 
early summer (April to July) with peak incidence in May, but it can occur throughout 
the year (Doxey et al., 1991c; Milne et al., 1994). It is observed that the majority of 
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outbreaks occur during cool (7-11 °C) and dry weather with irregular ground frosts 
(Doxey et al., 1991c; McCarthy et al., 2001). WOOD et al. (1998) reported that 66% 
of cases occurred following a two weeks period of predominantly dry weather, 
followed by rains. Horses which had recently moved to a different pasture contract 
the disease more than those which have spent more than two months on the 
premises (Gilmour and Jolly, 1974: Doxey et al., 1991c). It is noted that 45 % of 
cases are due to moving from one pasture to another (Doxey et al., 1991b). Most 
incidences are associated with pastures where the disease has previously occurred 
(Gilmour and Jolly, 1974; Newton et al., 2004). GILMOUR and JOLLY (1974) 
reported that a higher proportion of horses which experience GS were receiving 
either no supplement or only concentrates than of those receiving hay and 
concentrates. McCARTHY et al. (2004) observed that feeding hay or haylage was 
associated with a decreased risk of disease, change of feeding type or quantity 
during the 14 days prior to disease was associated with increased risk, and the use 
of ivermectin was also associated with a significant increased risk of EGS. In 
contrast, WOOD et al. (1998) found no evidence that the supplementary feeding of 
hay or forage alone was associated with a decreased risk of the disease. It is 
suggested that the incidence might be reduced by stabling, even part-time (Gilmour 
and Jolly, 1974). Young animals, usually 2-7-year-old, are more susceptible (Gilmour 
and Jolly, 1974; Doxey et al., 1991c), with peak incidence among 3-5-year-old 
animals (Doxey et al., 1991b). However, GS was reported in horses from one year to 
over 20 years old and is of very rare occurrence during first year of life (Greig, 1942). 
Suckling foals below six months of age, despite ingesting significant volumes of 
grass, rarely develop the disease. Whether this apparent protection is due to 
maternally derived colostral antibodies, age-related differences in physiology, toxin 
metabolism or the way ingesta is processed is unknown (Cottrell et al., 1999). All 
breeds appear to be equally susceptible, asses and mules are very rarely kept in the 
affected districts and it is possible that they may be susceptible (Greig, 1942). In a 
recent study (Newton et al., 2004) to identify risk factors associated with recurrence 
of EGS on a previously affected premises in UK, there was an increased rate of 
recurrence with higher number of horses, presence of younger animals, stud farms 
and livery/riding establishments, loam and sand soils, rearing of domestic birds and 
mechanical droppings removal. While rate of recurrence decreased with chalk soil, 
cograzing ruminants, grass cutting on pastures and removal of droppings by hand. 
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Also, the disease was found associated with increased soil nitrogen content and 
pasture disturbance (McCarthy et al., 2004a). Prior contact with EGS is associated 
with a ten-fold reduction in the likelihood of the disease (Wood et al., 1998). 
However, GILMOUR and JOLLY (1974) reported no difference in frequency of the 
disease between animals with previous contact and those which had no previous 
contact with it. Confirmed recurrence of the disease in the same animal was not 
reported (Newton et al., 2004). In a study conducted by WOOD et al. (1998), it was 
observed that female horses had a three-fold reduction in risk compared to males; 
however, this was because female horses had far bigger number than males 
(Hedderson and Newton, 2004). Stresses such as recent purchase, travelling long 
distances, mixing with strange horses, castration, and foaling have shown to have 
effect. DOXEY et al., (1991b) found that horses in good body condition were more 
likely to contract the disease. However, a work by WOOD et al. (1998) did not 
support these findings. 
 
Latency of the disease is proposed to be 1-3 weeks, but can be as short as 2-5 days 
after animals being put out on grass (Guthrie, 1940; Doxey et al., 1991c). Incidence 
rate is low; it is reported that EGS affects 2-4 % of equine population in all breeds 
throughout the British Isles (Greig, 1942; Gilmour and Jolly, 1974; Gilmour, 1987; 
Doxey et al., 1991b; Newton et al., 2004);  but the disease is invariably fatal 
(mortality may exceed 95 %) (Gilmour and Jolly, 1974). It is proposed that the 
disease is not contagious, but that there appears to be an association with particular 
premises (Gilmour and Jolly, 1974). MILNE (1997a) found no evidence that the 
disease can be transmitted naturally between horses.  
 
2.1.5 Pathogenesis  
The mechanism of action of the putative neurotoxin remains unknown. It is 
hypothesized that the putative neurotoxin may be ingested, elaborated in the gut or 
produced by hepatic metabolism (Sharp, 1987; Hunter et al., 1999). However, the 
neurotoxicity of nitric oxide, which can be synthesized in excess by nitredergic 
neurons due to their activation by some agent such as grass secondary metabolites, 
is also suggested (Cottrell et al., 1999). Putative neurotoxins mostly proposed are 
botulinum neurotoxins, pasture mycotoxins and grass secondary metabolites (Cottrell 
et al., 1999). The putative neurotoxin exerts its action either directly or after a 
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predisposing factor. Tocher et al., (1923) proposed gastric irritation as a predisposing 
factor to C. botulinum. COLLIER et al. (2001) suggested Fusarium germinearium to 
cause the gastric irritation which was proposed by Tocher and his colleagues. Also, 
HUNTER et al. (1999) and COLLIER et al. (2001) thought that C. botulinum can be 
an opportunist due to any factor causing gut stasis. Furthermore, J. K. Miller and I. 
R. Poxton, Edinburgh, hypothesized that both a nutritional trigger and the 
intestinal immune status to C. botulinum are involved in the pathogenesis of 
the disease (Cottrell et al., 1999). 
 
As many EGS features can be produced by BoNT/C (Cottrell et al., 1999; Hunter et 
al., 1999), it is worthfull to suspect the actions of BoNT/C. BoNT/C has a unique 
neurotoxicity in that it is the only botulinum neurotoxin that can cause overt neuronal 
degeneration (Williamson et al., 1995). It is therefore possible that BoNT/C can 
cause damage to a wide range of neurons in vivo. BoNT/C1 inhibits the release of 
acetylcholine at cholinergic nerve terminals leading to flaccid paralysis, which could 
account for the signs of autonomic dysfunction of the GI tract. C2 is known to inhibit 
neutrophil migration which could account for the characteristic absence of 
inflammatory reaction in EGS, and it is also known to enhance neurosecretory 
release and hypersecretion, a likely feature of EGS (Cottrell et al., 1999). C3 can 
cause neuronal degeneration in vitro (Williamson and Neale, 1998) and hence it can 
account for the chromatolysis in EGS. There are two possible routes by which the 
putative neurotoxin affects the neurons; by direct action on the perikaryon or via the 
axon (Griffiths et al., 1994b). All the three toxin types of C. botulinum type C might be 
involved in producing the typical pathology of EGS (Cottrell, 1999; Hunter et al., 
1999). 
 
It is thought that the neurotoxin reaches the peripheral autonomic ganglia via 
circulation and/or by retrograde axonal transport (Griffiths et al., 1994b). Evidence of 
retrograde axonal transport has been shown experimentally by GRIFFITHS et al. 
(1994a). There was evidence suggesting that EGS agent may cross the placenta; 
when a full-term foal born by caesarean section to a mare with acute grass sickness. 
The foal lived for only 24 hours and was found, on histological examination, to have 
some of the lesions associated with grass sickness. These lesions had been caused 
presumably by a placenta-crossing factor, which was therefore likely to be present in 
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the blood of acutely affected animals (Gilmour, 1973b). However, a preliminary study 
done by WHITWELL (1992) showed that the putative neurotoxin does not appear to 
cross the placenta.  
 
It is suggested that the neuronal damage starts in the enteric nervous system 
(Bishop et al., 1984; Hodson and Wright, 1987), where the putative neurotoxin 
appears to be non-specific to neuronal type (Sabate et al., 1983). There is a 
correlation between the clinical severity and the extent and distribution of enteric 
neuronal damage (Doxey et al., 1992; Pogson et al., 1992; Scholes et al., 1993) with 
the greatest neuronal loss usually observed in the ileum. Damage to peripheral 
nervous system in EGS involves, beside enteric nervous system, some of 
paravertebral, prevertebral, dorsal root and ciliary ganglia (Cottrell et al., 1999). 
However, the damage in the CNS is usually less severe, focally, widely distributed 
and mainly seen in the spinal cord, specific brain stem nuclei and some of cranial 
nerves (Gilmour, 1973a; Wright and Hodson, 1988).  
 
The agent of EGS exerts its main effects on the GI tract. In acute cases, stomach 
and small intestine are rapidly distended with fluids, indicating a hypersecretory 
characteristic of the cause. This abdominal distension causes intestinal ileus, colic 
and dehydration (Cottrell et al., 1999). Also, this hypersecretion leads to reduced 
circulatory volume and may cause death from cardiac failure. Due to the neuronal 
damage and consequently partial or complete paralysis of the GI tract, especially in 
the acute disease, signs of autonomic dysfunction such as dysphagia, failure of 
oesophageal peristalsis and drooling of saliva are prominent. 
 
Involvement of nitrergic neurons is also suggested in ED and consequently increased 
nitrergic neuronal activity and increased synthesis of nitric oxide, which has 
excitotoxic (Patel et al., 1996) and anti-inflammatory (Alican and Kubes, 1996) 
actions, which can account for most of EGS features (Cottrell et al., 1999). 
 
2.1.6 Clinical features 
Clinical signs of equine grass sickness are described by many authors (Pool, 1927; 
Edwards, 1987; Pinsent, 1989; Milne et al., 1994; Milne, 1996; Mair and Hillyer, 
1997) and are mainly due to partial or complete paralysis or stasis of the GI tract and 
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its autonomic dysfunction. The signs occur in three overlapping forms, acute, 
subacute and chronic, classified on the basis of duration and severity of clinical 
signs. 
 
In the acute form the onset is sudden and the signs are severe and usually death 
ensues or the animal has to be euthanised within two days. The signs of acute form 
are frequent mild to severe abdominal pain (colic), massive abdominal distension due 
to accumulation of fluids in the stomach and small intestine, marked difficulty in 
swallowing (dysphagia), slow mastication, dropping food from the mouth, 
spontaneous nasogastric reflux of foul smelling green or brown stomach fluid, patchy 
or generalised sweating, excessive salivation, fine muscle tremors and on rectal 
examination small firm faecal pellets covered with mucus in the rectum, and the 
colon is heavily impacted with dry ingesta. In addition, the animal is depressed, with 
tachycardia (70-120 beats/min), gut sounds are usually decreased, reduced urine 
output, the rectal temperature is normal or there may be pyrexia of up to 39.5 °C and 
ptosis of upper eye lids.  
 
Subacute cases show similar, but in general, less severe signs often without 
nasogastric reflux, most cases either die or have to be put to death within seven days 
of onset and few of them progress to chronic form. Some body weight loss and 
tucked-up abdomen appearance usually develops in subacute disease.  
 
In chronic GS the signs are less severe and may develop insidiously, but this form is 
predominantly characterised by a marked loss of weight and emaciation leading to 
‘greyhound‘ appearance and dry rhinitis causing snoring sound from the nasal cavity. 
Subclinical cases are thought to occur but have not been proven (Doxey et al., 1995; 
Milne, 1997b). 
 
Clinical features of EGS have several parallels to infant botulism in humans (a toxico-
infection) (e.g. dysphagia, constipation, diminished appetite, and spectrum of severity 
(Poxton et al., 1999). Various similarities as well as differences have been noted 
between cases of EGS and botulism (Walker, 1929; McGorum et al., 2003). 
Similarities include muscle tremors, dysphagia, ptosis, salivation, and tucked up 
abdomen. Differences include the presence of profound myasthenia and dilated 
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pupils, and the absence of tachycardia, sweating, rhinitis sicca, impacted faeces and 
histopathological changes in case of botulism.  
 
2.1.7 Pathology 
Post mortem lesions in equine grass sickness are not pathognomonic and are of less 
significance than the histopathological picture of autonomic neurons. Gross 
pathology of acute cases shows distension of stomach and small intestine with foul 
smelling fluid, secondary impaction of colon and caecum with dry ingesta, small 
faecal boluses covered by sticky mucus are usually found in the rectum, congestion 
of abdominal organs and very often there is colonic mucosal adhesion of blood 
products (Cottrell et al., 1999). There is usually splenomegaly (Greig, 1942; 
Mahaffey, 1959) and erosion of the oesophageal mucous membrane. Also, blackish 
batch at junction between ventricles and auricles and marked congestion in vessels 
of nasal septum were observed (Tocher et al., 1923). Subacute cases have less 
severe abnormalities, have little or no gastric or small intestine distension, have 
varying degrees of secondary impaction of large intestine and often have rhinitis 
sicca. The most prominent feature of chronic cases is cachexia, due to inanition or 
maldigestion and malabsorption, with stomach and small intestine usually being 
relatively empty (Cottrell et al., 1999). Necrosed or decayed ethmoid bone, which 
often leads to secondary inflammation of the brain and spinal cord, was also reported 
(Tocher et al., 1923). 
 
The histopathological changes in equine dysautonomia are mainly seen in the 
autonomic neuronal cells. ED is associated with characteristic degenerative changes 
in the peripheral autonomic ganglia, neurons of the enteric nervous system, certain 
brain stem nuclei and often more restricted changes in sensory ganglia (Obel, 1955; 
Mahaffey, 1959; Pogson et al., 1992). The main alterations in the nerve cells are 
axonal dystrophy, cytoplasmic vacuolation, pyknotic and eccentric nuclei, 
margination or loss of Nissl bodies, increased numbers of lysosomes and 
mitochondria which assume a central location and loss of a recognisable Golgi 
structure (Gilmour 1974, Hodson and Wright, 1987; Griffiths et al., 1993). However, 
all the grades of cell degeneration from early chromatolysis to death and 
disintegration were encountered (Mahaffey, 1959). 
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It is suggested that the neuronal damage starts in the enteric nervous system 
(Bishop et al., 1984; Hodson and Wright, 1987), where the putative neurotoxin 
appears to be non-specific to neuronal type (Sabate et al., 1983). A correlation 
between the clinical severity and the extent and distribution of enteric neuronal 
damage has been found (Doxey et al., 1992; Pogson et al., 1992; Scholes et al., 
1993) with the greatest neuronal loss usually observed in the ileum. Neuronal lesions 
in acute cases are seen in the stomach and both small and large intestine (Scholes 
et al., 1993; Murray et al., 1997) and localised in the distal small intestine in chronic 
cases (Scholes et al., 1993). Damage to peripheral nervous system in EGS involves, 
beside enteric nervous system, some of paravertebral, prevertebral, dorsal root and 
ciliary ganglia (Cottrell et al., 1999). However, the damage in the CNS is usually less 
severe, focally, widely distributed and mainly seen in the spinal cord, specific brain 
stem nuclei and some of cranial nerves (Gilmour, 1973a; Wright and Hodson, 1988). 
These neuronal elements are not always affected to the same degree (Pogson et al., 
1992). A study conducted by MARRS et al. (2001) showed moderate hepatocellular 
pathology in conjunction with steatosis and cholestasis in GS cases. 
  
The involvement of nitrergic neurons in EGS is suggested (Cottrell et al., 1999). It is 
observed that the anatomical distribution of neuronal nitric oxide synthase neurons 
bears a remarkable similarity to the distribution of neuronal damage which occurs in 
EGS. The relative absence of lesions in the cerebral cortex in EGS (Barlow, 1969) 
may reflect the fact that the cortex contains few nitrergic neurons (Snyder and Bredt, 
1992).  
 
2.1.8 Diagnosis 
There are no pathognomonic macroscopic findings at ante mortem or post mortem 
examination and the diagnosis can only be confirmed by histopathological 
examination either of the sympathetic ganglia and/or ileal tissue at post mortem or of 
the ileal biopsies obtained at laparotomy from living animals (Scholes et al., 1993). 
Diagnosis based on the demonstration of non-inflammatory neuronal degeneration 
(chromatolysis and necrosis) on histopathological examination of enteric tissue is 
extremely accurate (Scholes et al., 1993). Because laparotomy has its adverse effect 
on case survival (Milne et al., 1994), the ante mortem diagnosis must rely heavily on 
the epidemiological factors, clinical findings and the elimination of other possible 
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causes of colic, impaction, dysphagia, food discharge and weight loss (Doxey et al., 
1991b). MILNE (1991) and DOXEY et al. (1995) mentioned that the accuracy of 
diagnosis based on clinical signs of autonomic failure without ileal biopsy may reach 
98 %. GREET and WHITWELL (1986) and MILNE (1996) have suggested the usage 
of contrast radiography if doubt exists in case of dysphagia and to demonstrate 
oesophageal dysfunction. Endoscopy also has been proposed as diagnostic aid. 
Ocular administration of phenylephrine (alpha-adrenergic agonist) as a mean to 
diagnose GS was studied by HAHN and MAYHEW (2000). A significant greater 
mean increase in the size of the palpebral fissure was found in GS cases compared 
to controls.  
 
Laboratory tests showed marked increase in plasma levels of adrenaline and 
noradrenaline (Hodson et al., 1984; Hodson et al., 1986) and dopamine-beta- 
hydroxylase (Griffiths et al., 1993), which is associated with noradrenaline synthesis, 
in blood of grass sickness cases. This increase in catecholamines may account for 
the generalized sweating and atony of the GI tract. MAHAFFY (1959) found no 
biochemical or haematological abnormalities. However, examination of blood 
parameters (Stewart et al., 1940; Milne and Doxey, 1990; Doxey et al., 1991d) 
indicated hypovolaemia and increase in plasma protein, sugar and specific gravity. In 
addition, on examination of urine from GS cases, the specific gravity was higher than 
normal, glucose was detected, elevated total protein and pH was less than normal 
(Marrs et al., 1999), which were attributed to either kidney damage, increased levels 
in plasma or dehydration. However, this was criticised by KERR (1999) because only 
4 affected horses were studied and the method used to analyse the urine was not 
optimal. 
   
Differential diagnosis in GS is important to eliminate other possible causes of colic 
and impaction such as primary colonic impaction/displacement/torsion, colitis, caecal 
impaction, small intestinal obstruction, intestinal intussusception, peritonitis and 
enteritis (Milne, 1996). Also, other causes of dysphagia and food discharge such as 
classic botulism, pharyngitis, pharyngeal paralysis and oesophageal obstruction or 
ulcers should be considered. Due to some clinical and histological overlap between 
EGS, EMND (equine motor neuron disease) and EDM (equine degenerative 
myeloencephalopathy), similarities are suggested, but not confirmed. GERBER 
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(1994) and FATZER et al. (1995) hypothesized that EGS and EMND may be different 
manifestations of the same underlying disease process. However, DIVERS et al. 
(1994; 1997) took the view that the disease appears to represent a distinct clinical 
syndrome due to its completely different epidemiology, beside major differences in 
the clinical picture.  
 
2.1.9 Treatment 
The disease is invariably fatal and treatment should not be considered for acute and 
subacute cases and euthanesia is indicated (Milne, 1997b). Most authors consider 
that the prognosis is also hopeless in chronic cases and no useful treatment (Greig, 
1942; Gilmour, 1988; Pinsent, 1989). On the other hand, there are several reports of 
successfully treated and recovered chronic cases (Milne and Wallis, 1994; Milne et 
al., 1994; Doxey et al., 1995; Milne, 1997; Doxey et al., 1998). However, only horses 
with the mildest chronic form of the disease can be successfully nursed to recovery 
(Doxey et al., 1995).  
 
In general the prognostic indicators to select a case for treatment are the degree of 
dysphagia, appetite, the severity of colic, the audibility of gut sounds and the severity 
of rhinitis (Milne et al., 1994). Intensive and thorough nursing care is the mainstay in 
the treatment (Doxey et al., 1998). A case having been selected for treatment, the 
feed should be considered next; a high energy, high protein diet which is easily 
swallowed should be fed. Diazepam as an appetite stimulant and oral electrolytes 
can be given (Milne, 1997). Analgesics such as non-steroidal anti-inflammatory 
drugs, lubricants (purgatives must be avoided) and probiotics to improve gut flora can 
be given. Also, cisapride, a prokinetic agent, was used for the treatment of chronic 
GS by MILNE et al. (1996) and it was beneficial but expensive and accurate case 
selection should be undertaken. The rate of passage of digesta and dry matter intake 
was found significantly increased. Cisapride enhances the release of acetylcholine 
from the postganglionic nerves of the myenteric plexus of the gut (Lee et al., 1984) 
leading to an increase in gut motility. Use of cisapride in horses with large colon 
motility dysfunction may be efficacious (Pakestraw, 2003). Moreover, cleaning, 
grooming, washing of sweaty areas and cleaning of nostrils is important (Milne and 
Wallis, 1994). In addition, frequent human contact is important in keeping the horse 
interested and stimulated. The recovery rate at best is approximately 40 %, but the 
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majority of recovered cases returned to normal working life (Milne and Wallis, 1994; 
Doxey et al., 1998). 
 
2.1.10 Control 
Some epidemiological evidences showed that resistance to EGS can occur in older 
horses; those have been in a particular pasture for longer time or those had a prior 
contact with the disease (Greig, 1942; Doxey et al., 1991b; Wood et al., 1998). This 
resistance may be in a form of an immune response to the aetiological agent (Hunter 
and Poxton, 2001). Suckling foals below six months of age, despite ingesting 
significant volumes of grass, rarely develop the disease. This apparent protection 
may be due to maternally derived colostral antibodies (Cottrell et al., 1999). In an 
experimental study, rising titres of specific systemic antibodies to surface antigens of 
C. botulinum type C and BoNT/C were detected in horses that had been in contact 
with EGS or that were grazing land where EGS had occurred frequently in the past 
compared to significantly lower levels of antibodies in horses with grass sickness 
(Hunter and Poxton, 2001). This finding indicates that horses with low levels of 
systemic immunity to these antigens may be more susceptible. Due to the 
association found between EGS and C. botulinum by TOCHER et al. (1923), a 
vaccination trial utilizing a toxin/antitoxin mixture, derived from known strains of B. 
botulinus (C. botulinum, probably type B) involving over 2000 horses on different 
farms were performed as randomised control trials (Tocher, 1924). A significant 
decrease in the mortality in the inoculated animals (1.5 %) compared to controls (10 
%) was found. These epidemiological and experimental data indicate that the 
disease can be controlled by vaccination. Recently, due to the most believed theory 
that EGS is a toxico-infectious form of botulism, experience of Neogen Corporation 
(USA) in equine botulism vaccine production and the good facilities for experimental 
vaccination-challenge studies at the Animal Health Trust’s Allen Centre for Vaccine 
Studies, it was recommended to produce a vaccine from C. botulinum type C toxoid 
against the disease (Hedderson and Newton, 2004). Incidence can be reduced by 
stabling, even part-time, during spring and early summer especially to young animals 
(2-7-year-old) and giving hay and concentrate supplement.  In addition, pastures of 
previous outbreaks should not be grazed (Gilmour and Jolly, 1974; Scholes et al., 
1993).  
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2.2 Botulism 
Botulism is a non-febrile highly fatal disease of animals and man caused by 
neurotoxins of Clostridium botulinum. It is characterized by partial or complete flaccid 
paralysis of the muscles of locomotion, mastication and deglutition due to inhibition of 
the release of the neurotransmitter acetylcholine by botulinum neurotoxins at 
cholinergic nerve endings (Kriek and Odendaal, 1994). Botulism occurs sporadically, 
but in intensively farmed animals, it is responsible for high mortalities (Smart et al., 
1983: Abbitt et al., 1984; Trueman, 1992). Animal botulism can be a public health 
problem, since humans can be intoxicated by ingestion of contaminated meat.  
 
2.2.1 Clostridium botulinum 
C. botulinum was first isolated by van Ermengem in 1897 in Belgium from salted 
ham. He named the organism Bacillus botulinus, which was later renamed C. 
botulinum (Hauschild and Dodds, 1993). C. botulinum encompasses a 
heterogeneous group of obligate anaerobic, spore-forming, Gram-positive rods 
(Rocke, 1993) that produces the most potent biologic toxin known. The bacterium is 
ubiquitous and is found in soils and organic matter worldwide. C. botulinum is either 
not a normal inhabitant of the gut (Ortiz and Smith, 1994), occasionally present 
(Ricketts and Greet, 1984) or may be present (McLoughlin et al., 1988).  
 
2.2.1.1 Nomenclature and taxonomy  
Based on the serological properties of the toxin they produce, C. botulinum strains 
are divided into seven types (A-G), named according to their chronological discovery 
(Table 1). Types A, B, E and F are mainly involved in botulism in man, whereas types 
C and D are responsible for botulism in animals. Type G, according to CDC (1998), 
has not been confirmed as a cause of illness in humans and animals. However, 
SONNABEND et al. (1981) reported the isolation of type G organisms and 
demonstration of its toxin in five human cases with sudden death in Argentina; also, it 
was found associated with infant botulism (Sonnabend et al., 1985). HOLDEMAN 
and BROOKS (1970) divided C. botulinum types A-F into three major groups 
according to their cultural characteristics and metabolic products (Table 2). Other 
clostridia that have cultural characteristics similar to those of C. botulinum and exhibit 
high relatedness (Collins and East, 1998) are also included in these groups. Group I 
(proteolytic) contains strains of type A, proteolytic strains of types B and F, and C. 
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sporogenes; group II (non-proteolytic) contains strains of type E and non-proteolytic 
strains of types B and F; whereas group III (non-proteolytic) includes strains of types 
C, D and C. novyi type A.  A few strains of types C and D are mildly proteolytic, but 
are nevertheless included into group III. A fourth group (proteolytic) includes strains 
of type G, but due to its distinct phenotypic and genotypic features, was put as a 
separate species, C. argentinense (Suen et al., 1988). Some non-toxigenic strains of 
C. subterminale and C. hastiforme are also members of group IV (Suen et al., 1988).  
 
Table 1:       Chronological discovery of different types of C. botulinum (Kriek and  
                    Odendaal, 1994; Sperber, 1982) 
  
C. botulinum type Discoverer Year 
 
A and B 
 
G. S. Burke* 
 
1919 
 
Cα 
 
I. A. Bengston 
 
1922 
 
Cβ 
 
H. R. Seddon 
 
1922 
 
D 
 
P. J. Du Toit and E. M. Robinson 
 
1928 
 
E 
 
Bier 
 
1936 
 
F 
 
Moller and Sheibel 
 
1960 
 
G 
 
Giminez and Cicarelli 
 
1970 
 
*Burke described type A and B for the first time, but type B may be the toxin 
discovered in 1896 by van Ermengem and type A may be the toxin discovered by 
Landman in 1904 (Sperber, 1982) 
  
 
Although most C. botulinum organisms produce a single type of BoNT, it is now 
recognized that some strains produce mixtures of two toxin types (viz. AF, AB, BA 
and BF [Franciosa et al., 1994; Cordoba et al., 1995]). Comparison of nucleotide 
sequences of BoNT genes does not agree with the four phylogenetic groups of 
organisms, suggesting that there has been lateral gene transfer of BoNT genes 
(Collins and East, 1998). Type C strains consist of two distinct subtypes, Cα and Cβ 
(Kriek and Odendaal, 1994). Type Cα produces C1 and lesser amounts of C2 and D 
toxins; Cβ produces C2 toxin and type D produces predominantly type D toxin along 
with smaller amounts of C1 and C2 (Jansen,1971). C3 (exoenzyme) is produced by 
both C and D. In a study conducted by OGUMA et al. (1986), it was found that 
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biochemical characteristics of C. botulinum type C and D differentiate them into four 
groups and not three as it is known  (Cα , Cβ and D). Also, OCHANDA et al. (1984) 
and OGUMA et al. (1984) found that classification of Cα, Cβ and D is not correct 
according to toxin reactions against antibodies raised against Cα, Cβ and D. They 
found four groups of reactions based on antigenic structure of toxins and relationship 
between toxin production and phages. The heterogeneity that exists in types C and D 
NTs has probably arisen from the mutation or recombination of phage genomes that 
is thought to occur during the cycles of curing and reinfection of type C and D strains 
in the environment (Sunagawa and Inoue, 1991). Group III organisms (C. botulinum 
types C and D, and C. novyi) toxins are each encoded on separate pseudolysogenic 
bacteriophages (Eklund et al., 1972). Cultures of toxigenic strains can be cured of 
their prophages and stop producing toxins and can be converted to toxigenic state by 
reinfection by phages (Oguma et al., 1986). The type of the toxin produced is 
determined by the specific phage with which the bacterium is infected (Eklund and 
Poysky, 1974; Eklund et al., 1974). Type C strains can be reinfected by either C or D 
bacteriophages, but strains of type D are infected only by the homologous phage. 
Also, C. novyi can be converted to either type C or D C. botulinum by phage type. 
Cured type C organism may continue to produce C2 toxin. This suggests that Cβ 
strains are derived from Cα strains upon loss of their prophage (Jansen, 1971). A 
cycle of phage loss and reinfection is thought to occur in vivo (Eklund et al., 1974). 
Some strains of C. butyricum and C. baratii produce NTs that cross-react with 
BoNT/E (McCrosky et al., 1986) and F (Hall et al., 1985) respectively. Some 
evidence suggests that the toxic factors may be transfered between different 
clostridia, when transfer of neurotoxigenicity from Clostridium butyricum to a non-
toxigenic Clostridium botulinum type E-like strain occurred (Zhou et al., 1993). C. 
butyricum and C. barrati toxigenic strains are genetically remote from group I-IV 
botulinum strains (Suen et al., 1988). Thus, six phenotypically distinct groups of 
clostridia are now known to be capable of producing BoNTs. Undoubtedly, additional 
serotypes will be identified in the future if for no other reason than mutations in the 
antigenic properties of existing toxins (Sperber, 1982).  
 
The taxonomic denominator for C. botulinum is the production of botulinum 
neurotoxin, which was first suggested by PRÉVOT (1953, cited by Collins and East, 
1998). However, neurotoxin production is not a stable phenotype in many C. 
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botulinum strains; other bacteria (viz. C. baratii and C. butyricum) are known to 
produce BoNT; some C. botulinum strains produce dual types of BoNTs; and non-
toxigenic organisms which contain silent BoNT genes are present (Collins and East, 
1998). So, nomenclature, which is rigidly based on BoNT production, is 
unsatisfactory and a major change is needed (Collins and East, 1998). The future 
nomenclature should take into account the phenotypic, genotypic and BoNT 
production characteristics. A sensible solution would be to designate each of the four 
groups as a separate species (Collins and East, 1998). Reclassification of C. 
botulinum was also suggested by HUNTER and POXTON (2002). For more details 
about complications of C. botulinum nomenclature, the reader is referred to COLLINS 
and EAST (1998). 
 
Table 2:  Phenotypic differences between organisms capable of producing 
botulinum neurotoxins (from Hatheway, 1998) 
 
 
Groups 
 
Other BoNT-producing Clostridium 
species 
 
Characteristic 
 
I 
 
II 
 
III 
 
C. 
argentinense 
 
C. 
butyricum 
 
 
C. 
baratii 
 
Toxin types 
 
A,B,F 
 
B,E,F 
 
C,D 
 
G 
 
E 
 
F 
Proteolysis + - - + - - 
Liquefaction of gelatin + + + + - - 
Fermentation of       
   Glucose + + + - + + 
   Fructose ± + ± - + + 
   Mannose - + + - + + 
   Maltose ± + ± - + + 
   Sucrose - + - - + + 
   Trehalose - + - - + - 
Lipase + + + - - - 
Metabolic acidsb A,iB,B,iV,PP A,B A,P,B A,iB,B,iV,PA A,B A,B 
Optimal growth 
temperature 
35-40 °C 18-25 °C 40 °C 37 °C 30-37 °C 30-45 
°C 
Minimal growth 
temperature 
10  °C 3.3 °C 15 °C  10 °C  
Spore heat resistance 
(temperature/D-value) 
112 °C/1.23 80 °C/ 
0.6-1.25 
104 °C/ 
0.1-0.9 
104 °C/ 
0.8-1.12 
  
Phenotypically related 
Clostridium species 
C. sporogenes  C. 
novyi 
C. 
subterminale 
  
 
+, all strains are positive; -, all strains are negative; ±, some strains are positive and some are 
negative. A, acetic; P, propionic; B, butyric; iB, isobutyric; iV, isovaleric; PP, phenylpropionic; PA, 
phenylacetic. 
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2.2.1.2 Botulinum neurotoxins 
C. botulinum produces seven neurotoxins that are pharmacologically similar, but 
serologically distinct from each other; designated as types A through G (Rocke, 
1993) according to their chronological discovery (Table 1). They are the most toxic 
biological substances known. The MLD for mice of BoNT type A per gram of body 
weight is 1.2 ng i.p., for type B is 0.5-2 ng i.p, C1 is 1.1 ng i.v, C2 is 1.2 ng i.p, D is 
0.4 ng i.p, E is 1.1 ng i.p and F is 2.5 ng i.v. (Gill, 1982). MLD of BoNT/C in cattle was 
found to be between 0.25 and 0.5 ng/kg body weight (Moeller Jr. and Davis, 2001). 
BoNT is produced as a complex with a group of neurotoxin associated proteins 
(NAPs). Botulinum neurotoxin complex is the only known example of a protein 
complex where a group of proteins (NAPs) protect another protein (BoNT) against 
the acidity and proteases of the stomach (Sharma et al., 2003). BoNTs are proteins 
which are produced intracellularly as protoxins and released into the culture 
supernatant in relatively low concentrations during logarithmic phase of growth and 
increase dramatically when cell growth ceases and bacteria undergo autolysis 
(Simpson, 1981). The toxic components are activated to the maximum toxic state by 
proteolytic enzymes. The proteolytic strains can activate their own toxins, while the 
toxins produced by non-proteolytic types are activated by exogenous proteases, such 
as trypsin in the host stomach (Sperber, 1982). However, the ability of trypsin to 
activate BoNT has been demonstrated for types A to G with varying degrees 
(Simpson, 1981). The toxins are initially synthesized as single chain polypeptides 
which are enzymatically cleaved to form the active dichain structure (heavy [H] and 
light [L] chains). The active form of BoNT is about 150 kDa, 100 kDa H chain and 50 
kDa L chain. The H chain consists of an amino-terminal 50 kDa domain (HN) and a 
carboxyterminal 50 kDa domain (HC) (Fig. 1). The proteins remain linked through a 
highly conserved disulfide bond (Pellizzari et al., 1999). Absorption of BoNTs is 
accomplished via endocytosis, primarily in the small intestine and only small amounts 
of protein escape digestion to be absorbed; however, the extremely high toxicity of 
BoNT can make even those small amounts extremely hazardous (Bonventre, 1979). 
Polypeptide subunits of BoNTs are bound to non-toxic neurotoxin-associated 
proteins which protect the toxins in the GI tract from acidic degradation. These 
proteins could conceivably block antigenic sites and prevent recognition of the toxins 
by the local antibodies.  
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The mechanism of action of BoNTs results from the specific binding of the heavy 
chain to the presynaptic membrane of cholinergic nerves (Pellizzari et al., 1999). 
Once bound, different H chain components facilitate internalization of the light chain 
within the nerve endings. The light chain, a zinc-dependent protease (Fujii et al., 
1992), degrades with high specificity the synaptic proteins that are involved in the 
fusion of synaptic vesicles with the plasma membrane, thus inhibiting release of 
acetylcholine, thereby producing a flaccid paralysis (Moriishi et al., 1996). Types A 
and E degrade SNAP-25; type B, D, F and G degrade VAMP/synaptobrevin; and 
type C1 degrades HPC-1/syntaxin (Moriishi et al., 1996) and SNAP-25 (Foran et al., 
1996). These three proteins form the synaptic SNARE complex. Once toxin is bound 
at the motor endplate, improved neuromuscular function is achieved only by the 
regeneration of new endplates, explaining the usual delay of four to ten days before 
noticeable clinical improvement occurs after initiating antitoxin therapy (Kriek and 
Odendaal, 1994). Each neurotoxin type has its own specific receptors, which may 
explain differences in species susceptibility to different toxin types.  
 
The genes of Type A, B, E and F NTs are likely to be present on the bacterial 
chromosome (Hauschild and Dodds, 1993), type G NT gene is contained within a 
plasmid, whereas C and D toxin encoding genes are present within bacteriophages 
(Rossetto et al., 2002). BoNT serotypes exhibit 30-60 % sequence identity (Szílagyi 
et al., 2000). However, serotype-specific antisera have been reported to elicit little or 
no cross-reactivity (Szílagyi et al., 2000). BoNTs within the same physiological group 
are almost identical, while the extent of diversity between NTs of the same serotype 
from different physiological groups is greater (e.g. Types A and B proteolytic are 
more related than types B proteolytic and non-proteolytic) (Henderson et al., 1997). 
BoNT/F gene sequence of C. baratii is different from BoNT/F gene sequence of both 
proteolytic and non-proteolytic strains of C. botulinum (Campbell et al., 1993).  
  
Recently BoNTs have become extremely useful therapeutic drugs; and the number of 
indications being treated by BoNTs is greatly increasing; including numerous focal 
dystonias, spasticities, tremors, blepharospasm, cosmetic applications, migraine and 
tension headaches, and other maladies (Johnson, 1999; Brin et al., 2002). The 
remarkable therapeutic utility of botulinum toxin lies in its ability to specifically and 
potently inhibit involuntary muscle activity for extended duration.  
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2.2.1.3 Growth requirements and cultural characteristics 
 
C. botulinum strains are motile, have peritrichous flagella, Gram-positive rods with 
subterminal oval spores which cause swelling to cells. Group I strains are straight to 
slightly curved, about 2-10 µm x 0.5-2 µm. In media with inadequate nutrients, they 
may increase in length to 20-45 µm (Kriek and Odendaal, 1994). The cells normally 
occur single and less often in pairs or short chains. They retain the Gram stain very 
well, often only becoming Gram-negative with the commencement of sporulation. 
Group II strains are straight rods which measure 1.7-15.7 µm x 0.8-1.6 µm, occurring 
singly or in pairs. Group III organisms are straight rods, with dimensions between 
3.0-22 x 0.5-2.4 µm. Colonies of C. botulinum strains are circular with an irregular 
edge and about 3 mm in diameter, which may increase to 8 mm after an extended 
period of incubation. Colonies are raised or flat, rough or smooth, and commonly 
show some spreading. However, the colony morphology of pure cultures of 
Clostridium species may be variable, so that the culture appears mixed. Subculture 
of single colonies yields the same variable types (Jousimies-Somer et al., 2002). The 
lipolytic enzymes produced by C. botulinum strains cause the development of a 
precipitate in an agar medium containing egg yolk underneath the colony and an 
irridescent film (pearly layer) covering the colony, both of which are due to the 
presence of free fatty acids (Kriek and Odendaal, 1994). Some strains of group III 
also produce lecithinase (zones of precipitation) (Segner et al., 1971).  In general, 
colonies of all groups of C. botulinum strains are usually surrounded by a narrow 
margin of complete haemolysis (Smith and Sugiyama, 1988). Anaerobe cultures are 
characterized by a foul odour due to volatile fatty acids, amine endproducts and 
hydrogen sulfide production (Jousimies-Somer et al., 2002). In general, the 
phenotypic characteristics vary greatly between Groups I to III and other BoNT-
L
Fig. 1:  Schematic structure of botulinum neurotoxin, showing   
             three functionally distinct domains (Hunter and Poxton,   
           2002). L, light chain; HN, N-terminal end of heavy chain;  
HC, C-terminal end of heavy chain.  
 
L HN HC
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producing Clostridium species (viz. C. argentinense, C. butyricum and C. baratii 
(Table 2). Group I organisms and C. argentinense are proteolytic, while others are 
non-proteolytic. C. botulinum strains produce lipase, while others do not. Different 
groups of C. botulinum and other species vary in their ability to ferment sugars, their 
optimum and minimum growth temperatures, resistance of spores to heat, and the 
metabolic acids they produce. 
 
Because no single procedure, no single medium or temperature of incubation is best 
for all toxin types and cultural varieties of C. botulinum, isolation of C. botulinum is 
difficult (Smith and Sugiyama, 1988). Also, C. botulinum is highly fastidious, and with 
the exception of some strains of group III bacteria, it is a strict anaerobe and even 
traces of oxygen in its environment can inhibit its growth (Kriek and Odendaal, 1994); 
and the bacteria can lose toxigenicity during isolation process (Smith and Sugiyama, 
1988). Deleterious effects of oxygen are also necessary to be avoided during 
transport and preservation of specimens. Cold temperatures will allow increased 
oxygen diffusion and reduce number of vegetative forms (CDC, 1998; Jousimies-
Somer et al., 2002). However, in nature the growth may happen in environment of 
low oxygen concentration. C. botulinum types A and B cultured in association with 
avian skin flora had similar growth patterns under both aerobic and anaerobic 
conditions (Dezfulian, 1999). Microbial flora in certain ecological habitats may 
actually promote the growth of C. botulinum through consumption of molecular 
oxygen and lowering of oxidation-reduction potential (Dezfulian, 1999). Moreover, the 
isolation of C. botulinum in environmental and food samples is frequently complicated 
by the presence of proteolytic and non-proteolytic non-toxigenic strains that both 
phenotypically and genotypically resemble C. botulinum and exhibit a high 
relatedness with their toxigenic counterparts (Lindström et al., 2001). From the 
literature, media used to isolate C. botulinum include Trypticase Peptone Yeast 
Extract Glucose, Robertson’s Cooked Meat Medium, Brain Heart, Chopped Meat 
Glucose Starch, Peptone-Yeast-Glucose, Reinforced Clostridial Medium (broth and 
agar), Egg Yolk Agar, and Blood Agar). Egg-meat medium fortified with 1 % additions 
of yeast extract, ammonium sulfate and glucose was found the best for growth and 
sporulation of C. botulinum type C (Segner et al., 1971). C. botulinum type C2 was 
detected by using trypticase peptone medium enriched with 1 % glucose (Nakamura 
et al., 1978). C2 is produced only during sporulation and not during vegetative 
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growth. A few selective media have been developed for isolation of C. botulinum. A 
selective medium, C. botulinum isolation agar (CBI), containing cycloserine, 
sulfamethoxazole and trimethoprim as inhibitory agents has been found suitable for 
isolation of group I C. botulinum from human faecal material (Dezfulian et al., 1981). 
CBI was later modified by MILLS et al. (1985) to botulinum selective medium, which 
enabled more rapid isolation of types A and B compared to CBI. Also, a selective and 
differential medium for isolation of the proteolytic group I strains was developed by 
SILAS et al. (1985). These media improve the isolation of some C. botulinum strains 
(Glasby and Hatheway, 1985), but they did not allow the growth of all C. botulinum 
strains (Whitmer and Johnson, 1988).  
 
The main limiting factors of growth of C. botulinum in foods are: 1) temperature, 2) 
pH, 3) water activity (aw), 4) redox potential (Eh), food preservatives, and 6) 
competing microorganisms (CDC, 1998). Low aw inhibits C. botulinum growth. A 
minimum aw of 0.94 is needed to support growth and toxin production. The optimum 
Eh for growth of C. botulinum is low (~ -350 mV) but toxin production has been 
observed at Eh of +250 mV. Because of this range, C. botulinum growth and toxin 
production can occur even in products considered to have a high oxygen level (CDC, 
1998). Growth and toxin production occurs in anaerobic condition at pH > 6.0 and not 
encouraged under acidic conditions such as those found in properly prepared 
haylage and silage. If the ensiling process is incomplete or circumvented, however, 
toxin production is possible (Galey, 2001). Usually growth and toxin production is 
limited or prevented at pH 4.6. However, it was reported to occur below this level 
(Raatjes and Smelt, 1979). C. botulinum grows optimally at a pH range of 7.0-7.6 
(Kriek and Odendaal, 1994). However, other pH ranges were reported; e.g. for type A 
and B, the pH range for growth was found 5.01-8.89 (Sperber, 1982). After being 
produced, BoNT viability was found not to be affected by pH in the range of 2.7-10.2 
(Halouzka and Hubálek, 1992). However, the toxin viability is greatly affected by the 
change in the temperature. In experimental work, toxin type C was inactivated after 
two days at 37 °C, two weeks at 28 °C, six months at 5 °C, five years at -20 or -70 °C 
(Hubálek and Halouzka, 1988). The optimum growth temperature for group I is 37 °C, 
group II is 28-30 °C and for group III is 40 °C (Smith and Sugiyama, 1988). If all types 
are being sought and only one incubator temperature can be used, 30 °C for five to 
seven days should be used (Smith and Sugiyama, 1988). Organic nutrient 
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requirements for growth and toxin production of groups I and II strains differ (Whitmer 
and Johnson, 1988). The most essential nutrients for group I were arginine and 
phenylalanine, which were not required by group II. Group II required carbohydrate 
energy source. Arginine (0.1 %) is a principal energy source for group I (Smith and 
Sugiyama, 1988).  
 
The requirements of C. botulinum spore germination are much less restrictive than 
those for growth. Most spores can germinate under conditions in which vegetative 
growth is impossible (Sperber, 1982). Spore germination was increased by L-alanine 
and L-lactate or bicarbonate ions (Alberto et al., 2003). Germination of spores of 
proteolytic C. botulinum type B was strongly triggered by L-alanine/L-lactate/NaHCO3 
(Broussolle et al., 2002). PLOWMAN and PECK (2002) found that optimum 
germination for non-proteolytic strains of type B, E and F occurred in L-alanine/L-
lactate. Sodium bicarbonate, sodium thioglycolate and heat shock each enhanced 
germination, but were not essential. It is recommended by SMITH and SUGIYAMA 
(1988) to add lysozyme (5µg/ml) to enrichment medium whether heated or not 
heated to stimulate germination of C. botulinum spores. Germination is also 
promoted by the addition of 0.1 % starch, which binds the long chain fatty acids 
capable of inhibiting spore germination (Kriek and Odendaal, 1994). Heat treatment 
can activate dormant spores to germinate. C. botulinum type A spores are fully 
activated for germination by exposing them to a temperature of 80 °C for 10-20 min 
(Kriek and Odendaal, 1994).  
 
For isolation of anaerobes, the primary plating media should be prereduced or freshly 
prepared (preferably less than two weeks old), but plates for subsequent subculturing 
do not need to be reduced (Jousimies-Somer et al., 2002). Also, liquid media for 
primary isolation have to be heated in a boiling water bath for 10 min to remove 
oxygen and then cool to room temperature (RT) (CDC, 1998). The inoculation should 
not be more than ten percent by volume of soil samples or 20 % of food (Smith and 
Sugiyama, 1988). As C. botulinum can be inhibited by other bacteria (Graham, 1978; 
Szabo et al., 1994; Sandler et al., 1998; Böhnel and Lube, 2000) such as C. 
perfringens and C. tetani (Smith, 1975; Smith, 1978), direct inoculation of specimens 
on agar media and heat and alcohol treatment are important. Sometimes the 
isolation is possible only if the specimens are treated with heat or alcohol before 
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incubation (Smith and Sugiyama, 1988). Direct streaking of specimens on agar 
medium was successfully used to isolate C. botulinum from infant botulism faecal 
samples (Glasby and Hatheway, 1985). Alcohol and heat treatment select for 
isolation of spore-forming bacteria, whereby all vegetative cells can be destroyed and 
this will eliminate the non-spore-formers that can compete with C. botulinum and 
adversely affect its growth (CDC, 1998). Alcohol treatment is better than heat 
treatment for low heat-resistant group II strains of C. botulinum (Smith and 
Sugiyama, 1988). However, spores of non-proteolytic C. botulinum heated at 95 °C 
for 15 min failed to be inactivated (Lund and Peck, 1994). In a study conducted by 
DAIFAS et al. (2003) to see the effect of ethanol on C. botulinum growth, they 
observed that the ethanol can extend the lag phase, decrease the exponential growth 
rate, and decrease the final level of growth in the stationary phase. The growth and 
toxin production was delayed by an ethanol concentration of 4 % and completely 
inhibited by 6 %. C. botulinum spores are resistant to heat, requiring temperatures of 
greater than 120 °C for destruction. Spores of different groups vary in their heat 
resistance (Table 2). Heating specimens at 80 °C for 10 min may be of advantage for 
group I strains as others may be destroyed. Low heating at 60 °C for 15-30 min for 
group I or intermediate heating of 71 °C for 15 min for group III was used (Segner et 
al., 1971). After heat test, if large numbers of other bacteria are present, it may be 
impossible to isolate C. botulinum from the plate and if so, alcohol treatment for 
spore selection has to be used (CDC, 1998). The disadvantage of heat and alcohol 
treatment is that non-sporulating strains may not be isolated (Dezfulian et al., 1981) 
and toxigenic strains may become non-toxigenic (Eklund et al., 1972). It appears that 
the highly toxigenic strains of all types tend to form fewer spores than the less 
toxigenic ones (Kriek and Odendaal, 1994). Enrichment cultures should preferably be 
incubated for 5-7 days, the period of active growth giving the highest concentration of 
bacterial toxin and sporulation (Smith and Sugiyama, 1988; Broussolle et al., 2002). 
Incubation for additional 10 days to detect possible delayed germination of injured 
spores, if no growth, is also indicated.  
 
Anaerobic incubation can be done in anaerobic chamber, anaerobic jars or by 
automatic systems such as the Anoxomat system. Recovery of anaerobes from 
clinical specimens has shown slight increase with the Anoxomat system compared to 
the conventional anaerobic jars and the anaerobic chamber (Jousimies-Somer et al., 
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2002). Phenylethyl alcohol in primary plates can inhibit swarming clostridia and 
facilitate isolation of other colonies (Jousimies-Somer et al., 2002). Plates for 
anaerobes should not be exposed to air until after 48 h of incubation, since 
anaerobes are most sensitive to oxygen during their logarithmic phase of growth. 
However, if on selective medium, the plates may be examined after 24 h of 
incubation since the selected organisms grow rapidly (Jousimies-Somer et al., 2002). 
Group I organisms of C. botulinum are more easy to be isolated than organisms of 
the other groups (Hatheway and McCroskey, 1987). C. botulinum was isolated from 
111 (out of 336) stool samples from infant botulism cases, which were all group I 
organisms (Hatheway and McCroskey, 1987). Addition of antibiotics to isolation 
media to isolate C. botulinum was frequently used (e.g. Dezfulian, 1981; Silas et al., 
1985). It is necessary to pick several lipase positive colonies because some isolates 
may be non-toxic (CDC, 1988). It may be difficult to isolate C. botulinum type E from 
mixed cultures because of bacteriocin produced by non-toxigenic organisms that are 
similar to C. botulinum; this can be overcome by using a medium containing trypsin, 
which inactivates the bacteriocin such as trypticase-peptone-glucose-yeast extract-
trypsine (CDC, 1998). As freezing may kill vegetative cells (Jousimies-Somer et al., 
2002, CDC, 1998), isolates must be stored in a sporulating form (5-7 days 
incubation). C. botulinum can lose its toxicity during isolation process (Collins and 
East, 1998), its isolation with stable toxigenicity is difficult (Hauschild and Dodds, 
1993), or even pure toxigenic cultures may become non-toxigenic (Eklund et al., 
1971).  
 
2.2.2 Botulism in animals 
Botulism is a non-febrile highly fatal disease of cattle, sheep, goats, horses, mules, 
donkeys and rarely pigs. Other animals such as dogs, birds, fish, minks, and certain 
laboratory animals are also susceptible (Smith and Sugiyama, 1988). Botulism was 
early reported in cattle by Le Vaillant in 1780-1785 (Kriek and Odendaal, 1994). 
Cattle are the most affected species. Sheep and goats are less commonly affected 
and outbreaks were reported in sheep more than in goats (Van Derlugt, 1995). 
Botulism can occur from exposure to BoNT by one of three possibilities. Most 
commonly by ingestion of preformed toxin (intoxication) associated with carcasses, 
decayed organic matter such as poorly ensiled haylage or silage or coprophagy (in 
case of poultry). Toxico-infectious botulism is another source of exposure in which 
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the organism grows in the gut and produces the toxin. This form of botulism was 
reported in foals (skaker foal syndrome; Rooney and Prickett, 1967), in adult horses 
(Hartigan, 1985), in chickens (Miyazaki and Sakaguchi, 1978), in pheasants (Kriek 
and Odendaal, 1994), and in cattle (visceral botulism; Böhnel et al., 2001). A similar 
TI occurs in human infants and adults. The TI form of botulism seems to be 
increasing. In France, the increasing incidence of animal botulism is supposed to be 
mainly due to the toxico-infectious form (Popoff and Argente, 1996; cited by Böhnel 
and Lube, 2000). Similarly, bovine botulism in Germany has increased due to the 
visceral form (Böhnel et al., 2001). The visceral form of botulism may occur without 
evidence of a major paralysis of locomotoric muscles (Böhnel et al., 2003). The third 
form of botulism is wound botulism (Swerczek, 1980), which results from infection of 
an anaerobic wound leading to toxin production. The wound can be inside the animal 
such as ulcers or necrotic lesions, which are encountered e.g. in shaker foal 
syndrome (Swerczek, 1980) or outside the animal as in case of tetanus. Animals are 
mostly affected by C. botulinum types C or D toxins and rarely by type A or B 
(Schocken-Iturrino et al., 1989; Seifert, 1996). Botulism in cattle has been associated 
with pica (aphosphorosis) (Kriek and Odendaal, 1994). Grazing pastures which have 
been spread with poultry litter occasionally containing decomposing chicken 
carcasses were the most common source of bovine botulism (Fach et al., 1996). 
Ensiled poultry litter was also reported to be implicated in outbreaks of bovine 
botulism (McLoughlin et al., 1988). Avian botulism is caused mostly by type C and 
involves large numbers of wild ducks and geese (Smith and Sugiyama, 1988). C2 
toxin has been implicated in some cases of type C botulism in broiler chickens where 
diarrhoea and enteritis have been observed alongside the neuroparalysis signs of 
botulism (Ohishi and Gupta, 1987, cited by Hunter and Poxton, 2002).  
 
A substantial quantity of ingested botulinum toxin is either not absorbed or destroyed 
by digestive processes. Small non-lethal doses of toxin ingested over a period of time 
will also cause intoxication, as BoNT has a cumulative action (Böhnel et al., 2001). 
Apparently there is a varying susceptibility to various BoNTs in man and different 
animal species, breeds and individuals (Smith and Sugiyama, 1988). However, the 
old belief that some types may not be toxic for different animal species or man is 
invalid (Kriek and Odendaal, 1994; Seifert and Böhnel, 1995). Absorption of toxin is 
accomplished via endocytosis, mainly in the duodenum (Miyazaki and Sakagushi, 
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1978), but also in the rumen (stomach), jejunum and ileum. The flaccid paralysis 
caused by the toxin develops as a result of the inhibition of acetylcholine release at 
the neuromuscular junctions. A progressively developing flaccid paralysis results; 
paralysis of muscles of respiration being the eventual cause of death. The paralysis 
in botulism spares CNS and sensory nerves. In addition, to neurotoxin, several other 
metabolic by-products contribute to pathogenesis (Seifert and Böhnel, 1995). The 
non-toxic components in BoNT are thought to be important in the pathogenesis of 
botulism as they protect the neurotoxin from proteases and acidity in the GI tract; the 
larger the progenitor complex the higher the oral toxicity (Hunter and Poxton, 2002).  
 
Severity of signs depends on type and quantity of toxin ingested and accordingly the 
disease has been divided into peracute, acute, subacute and chronic forms. The 
incubation period in cattle usually varies from 2-6 days, but deaths for up to 17 days 
may occur (Kriek and Odendaal, 1994). The duration of illness may be as short as 24 
h in peracute cases or up to 7 days or longer with chronic cases. Affected animals 
manifest partial or complete paralysis of muscles. Paralysis usually starts in hind 
quarter and then spreads to forelimbs, head and neck. The appetite is usually not 
affected, few animals may be constipated, ruminal tympany may develop, tongue 
often protrudes from the mouth, profuse salivation, and difficulty in chewing and 
swallowing occur; however, dysphagia is not a consistent finding. Tucked up 
abdomen is usually observed in chronic form. Signs due to type B toxin are markedly 
different from type C and D toxins (Kriek and Odendaal, 1994; Seifert, 1996). 
Anorexia, regurgitation of feed and water, profuse salivation, no ataxia, tail and 
tongue are not paralysed, are signs observed with type B.  
 
No specific treatment other than administration of specific or multivalent 
hyperimmune serum in the early stages of the disease is possible. However, the use 
of specific toxoids or antitoxoids is complicated by the possibility that more than one 
type of BoNT may be present in any case of botulism and it is difficult to determine 
the specific toxin early, if at all. So, polyvalent or bivalent antitoxin is usually used, 
e.g. C and D which are mixed immediately before injection. As the antisera are 
expensive and not easily attainable, they are generally used selectively for the 
treatment of valuable stock. Vaccination against botulism has been effectively used 
in South Africa (Kriek and Odendaal, 1994). Because the concentration of BoNT 
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required to induce clinical signs is low, recovered animals do not develop immunity 
(Coleman, 1998). Good nursing is essential when treating animals suffering from 
botulism. Rehydration, laxative in constipated animals, support of laterally recumbent 
animals especially ruminants, are important. Correction of phosphorous deficiency 
(pica), removal of source of intoxication, not to feed suspected feed or improperly 
made silage or haylage. No poultry litter should be used or to vaccinate before 
feeding it at first and thereafter immunize regularly, or sterilize it. Oral antibiotic use in 
botulism is controversial. Some authors claim that oral antibiotics (e.g. 
metronidazole, penicillin) do not eliminate C. botulinum from the intestinal tract of 
foals, while others note that these drugs may increase toxin release by killing the 
vegetative form of C. botulinum or may disturb the normal GI tract flora, favouring 
clostridial overgrowth (Semrad and Peek, 2002). Metronidazole is also reported to 
predispose laboratory animals and humans to botulism. Aminoglycosides, 
tetracyclines, procaine penicillin should be avoided as they may potentiate 
neuromuscular blockade (Semrad and Peek, 2002). So, antibiotics may be given only 
for secondary infections. 
 
2.2.3 Botulism in horses 
Horses are extremely sensitive to botulinum toxin. Amounts of toxin which are 
sublethal in mice may rapidly cause the death of adult horses if administered i.v. 
(Kinde et al., 1991). Exposure of the horse to botulism may occur from ingesting 
preformed toxin in contaminated feed (forage poisoning) or rarely may result from 
enteric (adult horses or very young horses [shaker foal syndrome]) or wound 
infection with C. botulinum and subsequently production of toxins in vivo (Galey, 
2001). Clinical paralysis and death may result within hours from exposure to a high 
toxin level or, as in many cases, may develop and progress over a period of two to 
three weeks or more.  
 
Forage poisoning was confirmed to be caused by C. botulinum by Graham and 
Brueckner in 1919 (Kriek and Odendaal, 1994). Forage is often the source, 
especially poorly ensiled silage or haylage and that contaminated with carrion. 
Forage poisoning most often is caused by consumption of feed contaminated with 
type B toxin (Galey, 2001).  In North America, horses are affected most frequently by 
type B botulism (> 85% of cases), occasionally by type C, and only rarely by type A 
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botulism (Galey, 2001). Type B and D have been reported in cases of equine 
botulism in England (Ricketts and Greet, 1984). Type C2 is also reported together 
with C1 causing botulism in horses (Kinde et al., 1991). In general forage 
contaminated with carrion tends to have type C or D toxin (Galey, 2001).   
 
Toxico-infection occurs mainly in very young horses (skaker foal syndrome) in the 
intestine, which is predisposed by ulcer or necrosis, and appears to be potentiated by 
excessive amounts of corticosteroids contained in the fat of the milk  of mares 
(Swerzek, 1980). TI botulism in foals (similarly in human infants) thought to be due to 
lack of an established normal gut flora that permits germination of spores and growth 
of C. botulinum in the GI tract (Bartlett, 1986). Shaker foal syndrome usually is 
attributed to type B toxin. However, a case of type C in a two-month old foal was 
reported (Semrad and Peek, 2002). It is sporadically occurs in foals between two 
weeks and eight months of age; mainly in the fast growing period at 2-4 weeks of age 
(Swerczek, 1980). Signs of shaker foal syndrome are stiff gait, muscular weakness 
and tremors (shaking prior to recumbency) without ataxia, dysphagia, decreased tail 
tone may also be noted, dyspnoea with extension of head and neck is seen as the 
disease progressed, recumbency and death that occurs more often 24-72 h after the 
onset of clinical signs (Swerczek, 1980). TI botulism in adult horses sporadically 
occurs (Swerczek, 1980; Hartigan, 1985) and is always associated with an altered GI 
environment; for example following GI disease, abdominal surgery, or recent 
antibiotic therapy (Chia et al., 1986). On one particular thoroughbred horse farm, 91 
cases of TI botulism occurred among foals, yearlings, and adult horses and only two 
animals survived, which showed typical clinical signs of botulism (Szabo et al., 1994).  
The equine grass sickness disease now is strongly considered as a TI form of 
botulism (Hunter et al., 1999; Böhnel et al., 2003). 
 
Wound botulism in horses is mainly reported due to type B (Whitlock and Buckley, 
1997). It has been associated with castration, inguinal or injection abscesses, trauma 
and surgery in adult horses and in foals with omphalophlebitis, umbilical hernias and 
with infected leg wounds (Whitlock and Buckley, 1997; Semrad and Peek, 2002).  
  
The clinical signs of equine botulism are the same regardless of the pathogenesis; 
however, subtle differences may be produced by the various toxin types (C versus A 
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and B). The time of onset of clinical signs of botulism of horses depends on the dose 
of toxin ingested or absorbed from GI tract or a wound. The first clinical signs are 
observed from 12 h to ten days following ingestion of the toxin. Generalized muscle 
weakness, dysphagia or both are first appear, decreased excercise tolerance and 
colic follow in some cases. Anorexia, labored breathing and increased salivation, 
mydriasis and ptosis may happen, decreased tail tone is often, decreased tongue 
tone, stiff stilled gait, but not ataxic, muscle tremor mainly in type C, increased heart 
and respiratory rate, urinary retention, constipation and ileus are common signs in 
recumbent horses with agonal signs and some peddling (Galey, 2001). Aspiration 
pneumonia may be a complication. Death is caused by respiratory paralysis. 
Recovery may occur in mildly affected horses.   
 
Definitive diagnosis of botulism in the laboratory is elusive. No pathognomonic gross 
or histological lesions and circulating toxin levels are often low (Galey, 2001). 
Analytical methods, such as the mouse bioassay, are of insufficient sensitivity 
relative to the extreme sensitivity of the horse (Galey et al., 2000). Horses are 
suggested to be 1-10,000 times more sensitive than the mouse bioassay (Kinde et 
al., 1991). Source material may have higher and more easily detectable toxin levels, 
but it is often unavailable for testing. So, diagnosis often depends on clinical signs, 
lack of post-mortem lesions and elimination of other potential neurological diseases. 
The major definitive test used to identify botulism toxin uses the mouse protection 
bioassay. Samples of source material (faeces, gut contents, liver) can be assayed. 
Recently, sensitive immunoassays such as ELISA test were developed for BoNT 
detection (e.g. Doellgast et al., 1993; Ferreira et al., 2003). However, immunoassays 
are most often less sensitive than the mouse bioassay. Culture of faecal material or 
intestinal contents and PCR assays may help to identify the bacterium (Szabo et al., 
1994; Fach et al., 1996). However, presence of C. botulinum naturally among gut 
flora makes this detection questionable if no toxin is detected in the sample.  
 
Treatment largely depends on supportive care and injection of antiserum (polyvalent 
or monovalent antitoxin), if done early before recumbency occurs it may be of benefit 
(Rocke, 1993).  Horses with mild disease may recover without antitoxin therapy. 
Antibiotic therapy to prevent bacterial growth e.g. in wound botulism or to treat 
complications of paralysis like aspiration pneumonia may be used. But drugs that 
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potentiate neuromuscular weakness (aminoglycosides, tetracyclines and procaine 
penicillin) should be avoided. Mineral oil may be used to combat ileus and 
constipation. In addition histamine blockers may be used to prevent gastric ulcers. 
Severely affected and recumbent animals may require ancillary therapy, including 
mechanical ventilation, bladder catheterization and oral alimentation (Whitlock and 
Buckley, 1997). Xylazine and diazepam can be used to sedate horses and foals that 
struggle excessively in recumbency. However, as with many diseases, the best way 
to deal with botulism is prevention. Good husbandry, check forage for carrion or toxic 
plants or other foreign matter, not to feed poor-quality hay to horses and prevention 
of wounds to occur and if be cleaned and treated, are important measures. 
Vaccination of valuable animals is done especially in endemic areas, however, the 
vaccines (toxoids) are not easy to obtain and are expensive. In southern Africa 
botulism is currently well controlled by vaccination, although sporadic outbreaks of 
the disease still occur (Kriek and Odendaal, 1994). The use of antisera in horses has 
been shown to reduce mortality rates from 80-30 % (Swerczek, 1980). 
 
2.2.4 Botulism in humans 
Humans are very sensitive to botulism. Minute quantities acquired by ingestion, 
inhalation or by absorption through the eye or a break in the skin can cause profound 
intoxication and death (CDC, 1998).  Lethal dose for man is 1x10-9 mg/kg (Bonventre, 
1979). With a few exceptions of type F botulism (Hatheway, 1993), the majority of 
human botulism cases worldwide are due to types A, B, and E toxins (CDC, 1998). 
There have been few reports of human botulism caused by type C (Segner et al., 
1971). It has been proposed that the human GI tract does not have receptors for 
BoNT/C thereby preventing translocation into the circulation (Maksymowych and 
Simpson, 1996).  Recently, there have been reports of human botulism caused by 
other BoNT-producing Clostridium species (viz. C. baratii BoNT/F; [Hall et al., 1985] 
and C. butyricum BoNT/E [McCroskey et al., 1986]).  Five clinical forms of botulism 
have been described in humans: 1) classic or food-borne botulism; 2) wound 
botulism; 3) infant botulism; 4) hidden botulism; 5) inadvertent botulism (Cherington, 
1998). The main sources of food-borne botulism are meat, fish, milk products and 
non-acid vegetables such as beans, peas and beets. Wound botulism was first 
discovered in 1943 when C. botulinum type A was recovered from a patient who died 
of flaccid paralysis (Hatheway, 1990). Wound botulism is the least common form of 
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botulism, rarely reported (Whitlock and Buckley, 1997); now it is associated mainly 
with illicit intravenous drug use (Baymiller, 2001). Only group I strains have been 
incriminated in this condition in humans (Smith and Sugiyama, 1988). In infant 
botulism spores of Clostridium botulinum are ingested and germinate in the intestinal 
tract. Infant botulism, first recognized in 1976 (Arnon, 1978), is now the most 
frequently reported form. Honey or Corn syrup in bottle feedings, dust and other 
materials in the environment seem to be important sources of spores (Doddsm 1993; 
CDC, 1998). Most cases of infant botulism were due to type A or B organisms of 
proteolytic group I, but organisms from other groups were also reported (Dodds, 
1993); in addition to incrimination of C. butyricum and C. baratii  (Hall et al., 1985; 
Aureli et al., 1986). Hidden botulism, the adult variant of infant botulism, occurs in 
adult patients who usually have an abnormality of the intestinal tract that allows 
colonization by Clostridium botulinum. Inadvertent botulism is the most recent form to 
be described. It occurs in patients who have been treated with injections of botulinum 
toxin for dystonic and other movement disorders.  
 
Independent of the toxin type, the clinical manifestation of all forms of botulism is 
similar. This typically includes a descending flaccid paralysis with dysphagia, a dry 
mouth, double vision, difficulty in swallowing, dilated pupils, dizziness and muscle 
weakness. These are accompanied by the paralysis of the more peripheral parts of 
the body, and finally by paralysis of respiratory muscles which may lead to death.  
 
The treatment of human botulism includes the administration of a therapeutic trivalent    
antitoxin (A, B and E) and intensive symptomatic treatment, particularly respiratory 
support.  
 
2.2.5 Diagnostics of botulism 
In view of the severity of botulism and the great hazard it poses to the food industry, 
the diagnostics of C. botulinum and its toxin are insufficient and still poorly developed 
(Robinson and Nahata, 2003; Gessler and Böhnel, 2003); and probably it is 
substantially underdiagnosed (CDC, 1998; Böhnel et al., 2001). A presumptive 
diagnosis is made on the basis of the history, clinical signs, negative post-mortem 
examination and exclusion of similar diseases. A definitive diagnosis depends on 1) 
the demonstration of botulinum toxin in the feed or source of intoxication, serum, GI 
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contents or wound of a patient; 2) demonstration of bacterial forms of C. botulinum in 
GI contents, internal organs or feed; or 3) detection of antibody response to C.  
botulinum in recovered patients (Smith and Sugiyama, 1988). Laboratory diagnostics 
include the conventional culture techniques to isolate the organism, biochemical 
testing, molecular and immunological typing, and some other methods. 
 
2.2.5.1 Culture and isolation 
The culture method is complicated by the fact that no growth media selective for both 
proteolytic and non-proteolytic C. botulinum are available. Moreover, the presence of 
non-toxigenic strains, closely resembling C. botulinum, in foods and environmental 
samples greatly complicates the isolation of C. botulinum (Lee and Riemann, 1970; 
Broda et al., 1998). Several other complications, which make the isolation of C. 
botulinum difficult, are mentioned above (2.2.1.3). The samples are cultivated as 
such, as well as treated with heat or ethanol in order to eliminate vegetative bacteria 
but not bacterial spores (Smith and Sugiyama, 1988). Strict anaerobic techniques, 
including deoxygenation of culture media and anaerobic incubation, are required for 
the successful cultivation of C. botulinum.  Detection of the organism from food that 
does not contain demonstrable toxin is inconclusive because of the abundant spores 
in the environment and in processed foods and their raw materials (Hyytiä et al., 
1999). However, isolation of C. botulinum from human faeces or gastric specimen 
also provides good confirmatory evidence, since C. botulinum is rarely, if ever 
encountered in human specimens in the absence of botulism (Dowell et al., 1977).  
Successful isolation of C. botulinum, using selective (Dezfulian et al., 1981; Silas, 
1985; Mills et al., 1985) and non-selective (Segner et al., 1971; Hatheway and 
McCroskey, 1987) media has been reported. Group I organisms of C. botulinum are 
more easy to be isolated than organisms of the other groups (Hatheway and 
McCroskey, 1987). 
 
2.2.5.2 Biochemical identification 
Several commercial biochemical test systems were used to identify or confirm 
identification of C. botulinum (e.g. API 20 A, Minitek Anaerobe, RapID ANA II, 
Anaerobic-Tek, MicroScan, Rapid ID 32 A). Contradictory reports on their ability to 
identify Clostridium spp. have been published (Lindström, 2003). Commercial 
biochemical tests have been shown to fail in identifying both group I and II organisms 
of C. botulinum (Lindström, 2003). Neither were they capable of distinguishing 
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between C. botulinum groups I and II from their non-toxigenic counterparts. These 
test systems are therefore not suitable for the identification of C. botulinum 
(Lindström, 2003). Organisms of the same group and the related bacteria can not be 
distinguished from each other by biochemical properties (Hunter and Poxton, 2002). 
The biochemical properties of the strains of the same group may vary considerably 
(Oguma et al., 1986). In some texts, type C strains are described as being negative 
in lecithinase (Oguma et al., 1986). However, SEGNER et al. (1971) reported that all 
type C strains examined were positive in lecithinase reaction. As for the fermentation 
of sugars, widely variable patterns have been reported (Oguma et al., 1986). 
Variations in fermentation patterns have been shown even between strains of the 
same type (Segner et al., 1971).  
 
2.2.5.3 Cellular fatty acid analysis 
Different types of C. botulinum could be differentiated according to the types of fatty 
acids they produce, by gas liquid chromatography (GLC) (Reiner and Bayer, 1978; 
Gutteridge et al., 1980; Ghanem et al., 1991). However, the organisms of the same 
group and the related bacteria may not be distinguished from each other (Ghanem et 
al., 1991).  
  
2.2.5.4 Mouse bioassay 
The mouse bioassay has been used for the detection of botulinum toxins and 
identification of toxigenic C. botulinum (Smith and Sugiyama, 1988; CDC, 1998). The 
method was described as the standard method for detecting, identifying, and typing 
of BoNTs. However, animal testing is increasingly restricted and the method is 
cumbersome, expensive, time consuming and is not suitable for examination of test 
samples containing other lethal substances (Dezfulian and Bartlett, 1985). The 
presence of other bacteria in faeces and necrotic lesions often prevents the isolation 
of C. botulinum and detection of NT in the mouse bioassay (Szabo et al., 1994). 
Detection of toxin in food and animal or human body is a definitive diagnosis 
(Whitlock and Buckley, 1997) and necessary because the mere presence of the 
organism is not a significant finding. However, the method is not sensitive enough to 
detect the very low levels of toxin in the test sample. Serum collected from horses 
affected with toxico-infectious botulism invariably tests negatively since the 
concentration of toxin in the serum is generally so low that the toxin can not be 
detected by conventional methods (Swerczek, 1980). Mice are injected i.p. with the 
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test toxin mixed with antitoxin and with the toxin alone. Survival of mice protected 
with botulinum antitoxin and death of unprotected mice constitutes a positive assay. 
Trypsinization is only rarely necessary for detecting BoNT (CDC, 1998). Trypsin 
activation of the culture supernatant is generally required when strains from group II 
C. botulinum are concerned (Duff et al., 1956). EKLUND and POYSKY (1972) found 
no significant increase in C1 and D toxin compared to A, B, E and F by addition of 
trypsin. However, trypsin activation of culture fluids was found necessary for the 
demonstration of most strains of types B, C, D and E (Smith, 1978) or types B to F 
often require trypsinization of their culture fluids (Smith and Sugiyama, 1988). Also, 
lethal activity of some strains of type D was found to be enhanced by trypsin (Moriishi 
et al., 1989). C2 is produced as a protoxin and requires trypsin to be activated 
(Eklund and Poysky, 1972). It will be necessary to prepare a freshly trypsinized fluid, 
as the continued action of trypsin may destroy the toxin (Solomon and Lilly, 1998). 
The test should be performed with two mice per each test (CDC, 1998; Smith and 
Sugiyama, 1988), but, may be for ethical reasons one mouse per test was also used 
(Sandler et al., 1993). Botulinum intoxication usually kills mice in 6-24 h, but delayed 
deaths occasionally occurre (CDC, 1998). Signs of botulism in mice begin with 
ruffling of the fur, followed in sequence by labored abdominal breathing, wasp-like 
narrowed waist, weakness of limbs, paralysis, and death due to paralysis of 
respiratory muscles (Smith and Sugiyama, 1988; CDC, 1998). False-positive results 
due to non-botulinum lethalities, e.g. endotoxins from Gram-negative bacteria, 
infection, tetanus toxin, chemicals, and trauma can be a considerable nuisance. Non-
specific death of mice was found to be reduced by high centrifugation and/or filtration 
of liquid culture (Solomon and Lilly, 1998), dilution of culture supernatant (Hatheway 
and McCroskey, 1987), overnight deep freezing of supernatant (Smith and 
Sugiyama, 1988), use of antibiotics (Sandler et al., 1993), addition of BSA, which 
eliminates non-specific reactions through the interaction of constituent serum 
immunoglobulin M with endotoxin material from Gram-negative microbiota (Solberg 
et al., 1985) and preinjection of mice with antitetanus in case of soil samples (Smith 
and Sugiyama, 1988).  
 
High detectability of different types of C. botulinum from naturally contaminated 
samples by the mouse bioassay was reported. For example, 67.5 % (n=77) 
(Zechmeister et al., 2002), 52 % (n=2,200) (Sandler et al., 1993) for Type C; 54 % 
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(n=122) (Böhnel, 1999) for all types. However, due to development of new molecular 
methods with increased sensitivity, the mouse bioassay is considered less sensitive 
(Szabo et al., 1993; Szabo et al., 1994b). The method failed to identify clinical cases 
of botulism in animals (Thomas, 1991; Trueman et al., 1992). Inconclusive results are 
sometimes obtained (Szabo et al., 1994; Böhnel, 1999). Cross-reactions were 
observed between e.g. type C and D (Jansen, 1971; Fach et al., 1996), F and E 
(Yang and Sugiyama, 1975). Some strains have been found to produce mixtures of 2 
types of toxins, A+F, A+B and B+F (Franciosa et al., 1994; Cordoba et al., 1995), and 
in this case it is necessary to use polyvalent antitoxins. Intestinal contents and faecal 
samples are the most suitable for testing by mouse bioassay. Liver, spleen and 
serum are also used, however, serum of sensitive hosts is rarely found positive 
(Swerczek, 1980; McLoughlin et al., 1988).  
 
2.2.5.5 Molecular detection methods 
The molecular detection of C. botulinum typically involves the detection of the BoNT 
gene, indicating the presence of the organism in a sample. The molecular 
approaches include the sensitive and specific polymerase chain reaction and the use 
of molecular probes (Campbell et al., 1993; Franciosa et al., 1994). A labelled 
molecular probe may be further hybridised to a homologous DNA sequence and 
visualized immunologically. Detection of organisms in environmental samples by 
PCR has become more common as the need to monitor specific pathogens (Hielm et 
al., 1996) or genetically modified organisms released into the environment (Steffan 
and Atlas, 1988) arises. Several reports showed that PCR amplification is a reliable 
alternative to the standard bioassay method for identifying BoNT-producing clostridia 
(Szabo et al., 1994a and b; Fach et al., 1996). PCR can be used to detect the 
bacteria in situ (without enrichment) (Williamson et al., 1999), after enrichment 
(Szabo et al., 1994b) or the toxin gene can be detected even in non-vegetative forms 
(Szabo et al., 1993). Detection of toxin gene in spores is important in case of 
environmental samples. In situ detection is important because culture enrichment of 
samples can result in competition between microbial populations that may inhibit the 
growth of the target organism (Sandler et al., 1998). Samples suitable for PCR are 
mainly intestinal contents, faeces and source of affection. Serum is not suitable as 
the bacteria are normally not found in the circulation. However, detection of C. 
botulinum after enrichment of serum samples by both PCR and bioassay was 
reported (Szabo et al., 1994b). PCR is more rapid than the bioassay and uses no 
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animals. Most of PCR protocols employ toxin type-specific primers as a single pair in 
the PCR and not more than one serotype may be detected at a time. Few other 
protocols employ more than one pair of primers at a time for simultaneous detection 
of more than one serotype at a time (multiplex PCR. e.g. Lindström et al., 2001). The 
disadvantage of PCR detection directly from a sample is the possible detection of 
dead cells due to intact DNA after cell lysis. This problem is overcome by combining 
enrichment procedures with the PCR protocol (Hielm et al., 1996). Alternatively, 
reverse transcription-PCR (RT-PCR) in which gene expression is detected rather 
than the gene itself, may be employed to distinguish viable and dead bacterial cells 
(McGrath et al., 2000). To increase the sensitivity of PCR assays, nested PCR 
protocols, which involve several subsequent amplifications, were developed 
(Kakinuma et al., 1997). The reported sensitivities of PCR vary form 10-12.5 fg of 
DNA (corresponding to 3-5 cells per reaction volume) (Szabo et al., 1993; Fach et al., 
1993) to 0.3 ng of DNA (Craven et al., 2002). PCR and PCR-based methods 
detectability of naturally infected samples varied between authors and groups of C. 
botulinum. For example, for types C and D, 31.2 % (n=160) (Fach et al., 1996); for C, 
88.9 % (n=18) (Williamson et al., 1999); for type B, 94 % (n=66) (Szabo et al., 1994b) 
were reported. PCR is found more sensitive than mouse bioassay by several authors 
(Fach et al., 1993; Szabo et al., 1993; Szabo et al., 1994b). However, false-negative 
results were shown by PCR (Fach et al., 1996). This was partly attributed to the 
presence of direct toxin and absence of C. botulinum cells and spores or in non-
detectable number plus PCR inhibitors.  Nonspecific or unexpected (false-positive) 
results by PCR were also reported. For example type B gene was detected in two C. 
subterminale cultures (Franciosa et al., 1994). Cross-reactivity between some toxin 
genes was reported. For example, type B toxin gene, in addition to type A, was 
detected in 43 type A strains, compared to only one by bioassay (Franciosa et al., 
1994). 
 
Several limiting factors, which can affect the PCR results, were reported. A major 
limiting factor in the application of PCR for natural samples is the isolation of 
template DNA of sufficient quality and concentration into a practical volume for PCR 
analysis (Szabo et al., 1994a). PCR inhibition was thought due to high concentration 
of template DNA and this was found correct after being treated by diluting the 
extracted DNA ten folds (Fach et al., 2002). WILLIAMSON et al. (1999) found that 
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further purification of extracted DNA was critical for successful amplification of 
BoNT/C1 gene by PCR. Without this purification step, organic materials which co-
purified with the DNA during the extraction process inhibited the enzymatic activity of 
the Tag DNA polymerase, preventing amplification. Specific primers for specific 
amplification of a unique fragment of a BoNT gene are also critical for successful 
PCR. If primers are not highly specific, non-specific or no products may be produced 
(Campbell et al., 1993). 
 
Other molecular methods used in diagnosis of botulism include the pulsed-field gel 
electrophoresis (PFGE), which has an excellent discriminatory power and 
reproducibility (Hielm et al., 1998). A PCR-based method, randomly amplified 
polymorphic DNA assay (RAPD), which is less reproducible but can be quickly 
performed, was also used (Hyytiä et al., 1999). Also, the rRNA gene restriction 
pattern analysis (ribotyping) has been used to identify C. botulinum (Hielm et al., 
1999). 
 
2.2.5.6 Immunological detection methods 
Several immunoassay methods have been reported for the detection of botulinum 
neurotoxins or their antibodies. However, many of these assays such as 
immunodiffusion assay (Ferreira et al., 1981), passive haemagglutination assay 
(Evancho et al., 1973), and radioimmunoassay (Boroff and Shu-Chen, 1973) have 
poor sensitivities or specificities, which decrease their diagnostic value. The most 
widely used immunoassay method is enzyme-linked immunosorbent assay (ELISA). 
However, many assays developed are less sensitive and specific than bioassay 
(Szílagyi et al., 2000). Many reports have shown that ELISAs developed for detection 
of botulinum toxins failed to detect the toxin in samples from a sound clinical 
diagnosis of botulism (Abbitt et al., 1984; Thomas, 1991; Trueman et al., 1992). To 
improve the sensitivity and specificity of ELISA, a variety of modifications to the test 
have been established (Doellgast et al., 1993; Roman et al., 1994; Szílagyi et al., 
2000). Modified ELISAs (ELISA-based methods) include ELISA-ELCA (enzyme-
linked coagulation assay) (Roman et al., 1994), chemiluminescence immunosorbent 
assay (CLISA) (Ligięza et al., 1994), and immunomagnetic separation (magnetic 
bead-ELISA) (Liu et al., 2001; Kourilvo and Steinitz, 2002). The principle advantage 
of magnetic beads is the separation and concentration of target antigens in complex 
media and increase of the reaction kinetics due to a potentially greater surface area 
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compared to solid phase in immunoassays (Bruno et al., 1996). Accordingly various 
ligands are incubated with magnetic beads and then assessed using either specific 
primary antibodies and a secondary enzyme-conjugate antibody or a specific primary 
enzyme-conjugate antibody. Some ELISA and ELISA-based methods with 
sensitivities approximately the same as that of mouse bioassay (Doellgast et al., 
1993; Szílagyi et al., 2000; Zechmeister et al., 2002; Ferreira et al., 2003) or more 
sensitive than bioassay (Roman et al., 1994) were established and described as a 
convenient alternative to the mouse bioassay. ELISA methods can be used to assay 
BoNTs directly in clinical specimens or foods (Potter et al., 1993; Rocke et al., 1998), 
after enrichment (Doellgast et al., 1993), in toxigenic colonies (Dezfulian, 1993); or to 
assay the botulinum antibodies in sera (Ricketts and Greet, 1984; Jubb and Ellis, 
1993). However, due to the possibility to find antibodies to BoNTs in normal animals 
in areas where botulism is endemic, false-positive results may be encountered by 
ELISAs developed for detection of antibodies (Gregory et al., 1996). Cross-reactivity 
between different BoNTs and related clostridia was reported. For example, cross-
reactivity was reported between types C and D, and C. novyi (Thomas, 1991), and A 
and B (Dezfulian et al., 1984; Franciosa et al., 1994).  
 
Recently, the sensitivity of immunoassay methods was greatly extended by 
development of immuno-PCR methods (Sano et al., 1992; Wu et al., 2001). It is an 
antigen detection system, in which a DNA specific molecule is used as the marker. 
Immuno-PCR allows the detection of protein amounts as low as a few hundred 
molecules. Using a microtitre plate technique for the detection of PCR products, 
immuno-PCR has been found most suitable for detection of C. botulinum in large 
number of samples (Fach et al., 2002). Immuno-PCR sensitivity was found approx. 
105 more sensitive than ELISA by SANO et al. (1992), which was described as the 
most sensitive method; and 1000-fold more sensitive than the ELISA by WU et al. 
(2001).  
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3 OWN INVESTIGATIONS 
 
3.1 Aims of the study 
The general objective of the present study was to investigate field samples, 
especially from equine grass sickness cases (a disease suspected to be caused by 
C. botulinum), for isolation and identification of suspected C. botulinum organisms.  
The specific aims were as follows: 
1. Usage of enriched media and culture techniques to isolate organisms that are 
phenotypically similar (in colony and cell morphology)  to C. botulinum from 
field samples obtained from: i) EGS cases (animal and environmental) 
samples together with control animal samples; and  ii) classical botulism-
suspected cases, suspected feed and soil, to compare results of isolation. 
2. Identification of C. botulinum-like isolates by mouse bioassay, polymerase 
chain reaction (PCR) and magnetic bead-enzyme-linked immunosorbent 
assay (MB-ELISA). 
3. Comparison of results of mouse bioassay with those from PCR and MB-
ELISA. 
4. Comparison of results of EGS cases samples with those of control animals to 
see if C. botulinum could be linked to EGS.  
 
3.2   Materials and methods 
 
3.2.1   Culture methods and isolation 
 
3.2.1.1  Test samples 
The samples investigated in the study are: 
- Equine grass sickness samples 
• British samples (the main samples in the study) 
• Non-British samples (from Germany, Austria, Dubai) 
- Botulism samples (bovine, equine, human, chicken and soil samples) 
 
The total number of samples investigated was 288; sample distribution according to 
source is shown in Fig. 2. The GS samples were collected and sent from Britain, 
where the disease is more prevailing. The samples were kindly provided by Prof. B. 
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McGorum and Dr. R. Pirie (University of Edinburgh). After receival, the samples were 
kept frozen at -80 °C until being processed. The GS samples were collected from 7 
acute GS cases, both from animals and their environment; together with control 
samples from four healthy horses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The GS samples from animal origin included tissues and contents of stomach, 
duodenum, jejunum, ileum, caecum, small and large colon, rectum, liver, spleen, 
tonsil, pharynx and faeces. The samples from the animal environment are different 
sorts of mud and water, different types of grass and plants, hay, soil, worm casts, a 
rabbit carcass, and faeces of a bird, pheasant and rabbit. Besides the EGS samples 
from Britain, samples from five GS suspected cases from Germany (faeces and 
intestinal contents), a GS confirmed case from Austria (contents of jejunum, ileum, 
small and large colon) and samples from a horse fed suspected soil in Dubai (liver, 
spleen, and contents of stomach, jejunum, ileum, caecum and small colon) were also 
investigated. The samples from Dubai were kindly provided by Dr. U. Wernery, 
CVRL. Fig. 3 shows the distribution of EGS samples according to sample type. 
Botulism (non-EGS) samples (Fig. 4) are mainly bovine (intestinal contents, faeces, 
Fig. 2: Diagram to show number and distribution of test 
samples according to source 
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and few tissue samples) and soil samples. In addition to few samples from horses 
(faeces), animal feed, chickens (intestine and liver) and man (stool and tissues), 
botulism samples were taken from the samples routinely sent to the reference 
laboratory for diagnosis of botulism in the institute (Institute of Tropical Animal 
Health, Georg-August-University, Göttingen). All the test samples in this study were 
tested for the presence of BoNTs by the standard mouse bioassay method by direct 
or after enrichment testing during the routine diagnostic work of the institute. 
According to the records of the institute, 81 samples (44 GS and 37 botulism) had 
evidence for BoNTs (Table 3). 
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Fig. 3:     Distribution of EGS samples according to sample type 
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                  Fig. 4:      Distribution of non-EGS samples according to sample type 
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Table 3: Mouse bioassay results of test samples* 
 
EGS samples  Non-EGS samples 
British Others Total 
After enrichment Direct After enrichment  
After 
enrichment 
Toxin 
neutra- 
lization  
Direct Heated 
(60 °C/30 min) 
Non-
heated 
 Heated 
(60 °C/30 min) 
Non- 
heated 
 
 
 
Direct 
 
Heated  
(60 °C/30 min) 
Non-
heated 
Total 
 
Total 
 
ABE 
 
3 
 
1 
 
5 
 
3 
 
2 
 
0 
 
14 
 
7 
 
0 
 
 
3 
 
 
10 
 
24 
 
CD 3 5 7 1 0 0 16 16 2 4 22 38 
 
ABE/ 
CD 
 
3 4 5 1 1 0 14 2 2 1 5 19 
Total 9 10 17 5 3 0 44 25 4 8 37 81 
 
 
* These data were obtained from the records of the routine diagnostic work of the institute. 
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3.2.1.2 Culture media 
Ingredients of all media were obtained from Merck (MERCK, Darmstadt) unless 
otherwise stated. Ingredients (except haemin, vitamin K1, blood and egg-yolk 
emulsion), for all media, were added to 1l demineralised water and dissolved in a 
boiling water bath. Haemin and vitamin K1 were added after dissolution and before 
autoclaving. Blood and egg yolk were added under aseptic conditions to sterile agar 
media. The pH of all media was adjusted to 7.0 ± 0.2 and all media were autoclaved 
at 121 °C for 15 min. Working solutions of resazurin, haemin and vitamin K1 were 
prepared according to HOLDEMAN et al. (1977) with some modifications (section 
7.2). Defibrinated horse blood was obtained from OXOID, Wesel; egg-yolk emulsion 
from BECTON DICKINSON, Sparks; haemin, L-arginine, trizma base and sodium 
bicarbonate from SIGMA-ALDRICH CHEMICALS, Deisenhofen. Composition of different 
media is shown in section 7.1. 
 
3.2.1.3 Culture and isolation procedures  
At the beginning, to choose one medium to work with as most likely the best one for 
growth of C. botulinum, different media were used as described below. Twenty-three 
samples (20 samples from botulism suspected cases, mainly bovine tissues and 
faecal samples together with few faecal samples from horses, and three soil 
samples) were tested. After culture of samples, isolation of suspected colonies 
according to culture procedures shown below and testing of isolates for toxicity in 
mice, a single broth and agar medium was selected to work with for the rest of 
samples. Several broth media (CM, EM, CMGS, BH, RCM, FAB and fFAB) and two 
agar media (FAA and BA) were used. The selection of best broth and agar media 
was done according to toxicity of suspected colonies isolated and best growth. Best 
growth and more toxic isolates were shown by fFAB and FAA, which were then used 
for culture and isolation. Also, fFAB and FAA were found better than BA and EYA 
(DIFCO, Detroit) for growth of reference strains of C. botulinum types A-F. Because 
strains of group I and III of C. botulinum are more important in this study and they 
can optimally grow at 37 °C and also because the number of test samples is large so 
that it is difficult to work with more than one temperature, a single temperature for 
growth (37 °C) was used. The anaerobic conditions were fixed automatically (90 % 
N2, 5 % H2, 5 % CO2; ANOXOMAT® SYSTEM, MART, Lichtenvoorde, Fig. 5). Liquid 
medium for all the work was used as 5-ml volume in screw-cap tubes. 
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Culture and isolation procedure was conducted in an aerobic chamber 
(STOLTENBERG-LERCHE, Düsseldorf, Fig. 6), which is with facilities to keep the inside 
environment sterile. About 0.5-1 g of each specimen was inoculated into two tubes of 
5 ml medium, one heat-treated (sometimes heat-treatment was done after 
enrichment) and the other not and incubated anaerobically for three days (rarely five 
days). Heat test was conducted mainly at 60 °C for 30 min and rarely 80 °C for 10 
min or 70 °C for 15 min. Heat test was performed for about half the number of the 
test samples. Direct streaking of plates was done for small portion of the test 
samples and the plates were incubated for two days. After inoculation, smears for 
Gram stain (modified Gram stain, Hucker, 1979, section 7.3) were made from 
specimens (if liquid or moist). After incubation, liquid cultures were streaked either 
only on FAA/E (FAA with egg yolk) or sometimes on both FAA/E and FAA/B (FAA 
with blood) and incubated anaerobically for two days. To obtain well-separated 
colonies, only one loopful was streaked on dried plates and in a four-quadrant 
fashion. Alcohol test was performed for about one third of test samples and mostly 
after broth enrichment. One ml of ethanol (99 %) was added to one ml of enrichment 
culture of the specimen in sterile tube, mixed and left for one hour at RT. Then 
centrifuged and the pelleted material was washed with sterile PBS and centrifuged. 
Plates were streaked by the pelletted material and incubated for three days. Each 
enrichment broth culture was smeared for Gram stain. After incubation, the streaked 
plates, either directly or after liquid enrichment, were observed for various colonial 
morphologies, and smears for Gram stain were prepared mainly from colonies with 
characteristics consistent with C. botulinum (pearly layer, zones of precipitation, 
raised or flat, smooth or rough). Plates were examined with a hand lens and 
sometimes with a photomicroscope. After examination of Gram-stained smears, the 
suspected colonies were subcultured on agar plates (mainly FAA/B) for purification. 
Purification mostly needed more than one subculturing process. Gram stain and 
subsequent subculturing was mostly done from the same single colony. The primary 
plates were often reincubated along with the subcultures for additional 48 h and 
inspected again for new morphotypes. Gram-stained smears prepared from 
specimens, enrichment broth culture or colonies were observed for cell morphology, 
Gram reaction, and spores (shape and location). Also, wet smears to test for motility 
of isolates were examined. After plates being apparently of pure colonies, a well-
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isolated one or more than one colony was put into 2 tubes (mostly FAB fortified with 
BH granules) and incubated anaerobically for two days or less often for five days. 
After the incubation, one tube was used for toxicity testing and toxin neutralization in 
mice and the second was stored at -20 °C. Isolates were also tested for their ability to 
grow in oxygen or contamination in aerobic conditions at 37 °C. Photos from 
important colonies and their smears were taken (ZEISS microscopes).   
          
       
                                                             
 
 
 
 
 
Fig. 5:  Anoxomat® system (MART)  
 
 
1
2
3 
  1 , Anoxomat, it automatically controls evacuation and filling of jars with gases, it 
checks for catalyst validity and leakage or tightness in jars. 
 2  , Pump for evacuation 
and filling of gases. 
 3  Cylinders for N2, CO2 and H2.    
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 , Keys for ventilation, light and U. V. lamps;    , mesh for sucking of air comming from outside;      , 
two U. V. lamps inside at the back for overnight use;     , device for gas and electric enlighting (flame). 
 
 
Fig. 6:  Aerobic chamber of STOLTENBERG-LERCHE 
 
 
 
 
3.2.2 Mouse bioassay  
The isolates tested for lethality for mice and afterwards toxin neutralization were the 
lipase- and lipase-/lecithinase-positive rod-shaped isolates, beside some lecithinase-
positive and lipase-/lecithinase-negative rods. Apparently pure isolates were 
subcultured into liquid medium (mainly fFAB) and incubated anaerobically at 37 °C 
for two to five days. After incubation, cultures were centrifuged at 4000 g for 20-30 
min. To test for toxicity, white mice of the institute‘s breeding station weighing 18-25 
g were injected i.p. with 0.5 ml of each isolate culture supernatant (Smith and 
Sugiyama, 1988; CDC, 1998). Convulsions and death of mice due to non-specific 
reactions from the medium constituents was oftenly observed during the first five-ten 
minutes after i.p. injection, when a medium containing meat particles was used, 
especially if meat proteolysis has taken place. This has been encountered by using 
FAB fortified with BH granules for toxicity test and the medium containing meat 
particles was used for primary isolation only. Then no such reaction was observed 
during the first hour. Mice were observed for four days for signs of botulism (ruffled 
fur, wasp waist, laboured respiration, paralysis) or death. Trypsinization was 
performed only if the isolate was lipase-positive rods and found negative without 
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trypsin. Trypsin solution (20 mg trypsin [SIGMA-ALDRICH CHEMICALS] dissolved in 10 
ml sterile demineralised water) stored at -20 °C was added to the culture supernatant 
as 1 % (v/v) followed by incubation at 37 °C for 45 min.  
 
Toxin neutralization tests were carried out for lethal isolates. Polyvalent antitoxins 
type ABE (AVENTIS BEHRING, Marburg), and monovalent antitoxins types C and D 
(ONDERSTEPOORT VETERINARY INSTITUTE (OVI), Onderstepoort) were mainly used. 
Also in some instances, monovalent antitoxin types A-E (ID-DLO, Lelystad) and 
types B and E (IBT) were used. Types F and G were not tested. Antitoxins were 
rehydrated and used according to manufacturer’s instructions. For ethical reasons, 
number of animal tests had to be kept low; so, initially polyvalent ABE or mixture of 
types C and D antitoxins were used, and then splitting into monovalent antitoxins was 
done when necessary. The antitoxin was mixed with 0.5 ml of supernatant and 
incubated at 37 °C for 30 min. The toxin-antitoxin mixtures and only toxin were 
injected into mice accordingly (Smith and Sugiyama, 1988; CDC, 1998). Mice were 
watched for four days. If mice injected with the toxin alone died and those injected 
with the toxin-antitoxin mixture not, the test was considered positive for that antitoxin. 
If all mice died, the test was repeated by using diluted toxins. Toxin dilution was 
made in gelatine phosphate buffer (GPB, pH 6.2).   
 
3.2.3 Polymerase chain reaction  
To test for C. botulinum types A, B, E and F toxin genes, a multiplex PCR assay, 
which was developed by LINDSTRÖM et al. (2001), was conducted. For C. 
botulinum type C toxin gene detection, a PCR method developed by Institute of 
Applied Biotechnology (IBT), University of Göttingen (unpublished data) was used. 
While for detection of C. botulinum type D toxin gene, a method established by 
TAKESHI et al. (1996) was adopted.  
 
3.2.2.1 Primers 
One set of oligonucleotide primers specific for each of type A, B, E and F (Lindström 
et al., 2001), type D (Takeshi et al., 1996), and type C (selected by IBT, unpublished 
data) were used. The sequence of the primer pair of type C (CP3-01 and CP3-02) 
used is: 5´-CTG AAA AAG CCT TTC GCA TT-3´ and 5´-TTG TGC CGC AAA AGT 
ATT GT-3´. Additional two sets of primers specific for type C neurotoxin gene, CS-11 
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and CS-22 described by TAKESHI et al. (1996) and BCS-1 and BCS-2 (TAKARA BIO, 
Otsu) were also used for some isolates. 
   
3.2.2.2 Isolates and culture 
The isolates tested by PCR were only those which showed positive toxin 
neutralization test by mouse bioassay (Table 6). The isolates for the PCR were 
cultured in either fFAB, CM, RCM or sometimes in two of them and incubated 
anaerobically for 48 h at 37 °C.  
 
3.2.2.3 DNA isolation 
DNA of all isolates was extracted according to a method developed by IBT, 
unpublished data. One millilitre of culture broth was aseptically pipetted into a sterile 
1.5 ml eppendorf tube. The tubes were then centrifuged at 5,000 x g for three min at 
4 °C. The supernatant was discarded and 0.5 ml of TE buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH 8.0) was added to the pelleted material and vortexed. Then the tubes were 
boiled for ten minutes to release the bacterial DNA and then centrifuged as before. A 
volume of 3 µl of each supernatant was used as template in the PCR mixture.  
 
3.2.2.4 PCR for types A, B, E and F  
Master mix. A master mix of reagents of 50 µl was used, which contained 5 µl of 
buffer II (INVITROGEN, Germany), 1 µl of each primer (0.3 µM) (SIGMA), 1 µl of DNA 
polymerase (DYNAZYMETM), 3.3 µl of MgCl2 (0.33 mM) (INVITROGEN), 3 µl of template 
DNA, and sterile deionised water to 50 µl. Buffer II (1.25 ml) contains: 200 mM Tris-
HCl (pH 8.4), 500 mM KCl, 15 mM MgCl2, 2 mM of each dNTP, thermostable 
AccuPrimeTM protein, and 10% glycerol. 
 
PCR amplification. A programmable thermal cycler (TGRADIENT, Biometra, Göttingen) 
was used for the PCR. Reaction mixtures were subjected to initial denaturation at 94 
°C for 10 min and 27 cycles of denaturation (95 °C for 30 s), annealing (60 °C for 25 
s), extension (72 °C for 85 s), and final extension at 72 °C for 3 min. DNA mixture of 
reference strains of C. botulinum types A, B, E and F as positive control and a 
negative control containing all of the reagents except template DNA were included in 
each PCR amplification. 
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3.2.2.5 PCR for types C and D 
Master mix. Fifty-µl master mix of reagents was used, which contained 5 µl of buffer II 
(INVITROGEN), 1 µl of each primer (for either type C or D), 1 µl of DNA polymerase 
(DYNAZYMETM ), 3 µl template, and sterile deionised water to 50 µl. Also, the following 
master mix was used for part of the isolates: 25 µl of Bioron master mix (BIORON, 
Ludwigshafen), 1 µl of each primer, 6.6 µl MgCl2 (0.66 mM) (INVITROGEN), 3 µl of 
template, and sterile deionised water to 50 µl. Bioron master mix (1.25 ml) contains: 
Taq DNA polymerase (0.1 unit/µl), antibodies to Taq DNA polymerase, 32 mM 
(NH4)2SO4, 130 mM Tris-HCl, 0.02% Tween-20, 3 mM MgCl2, dNTPs (0.4 mM of 
each of dATP, dCTP, dGTP, dTTP).  
 
PCR amplification. Using the aforementioned thermal cycler, the reaction mixtures 
were subjected to initial denaturation at 94 °C for 10 min and 30 cycles of 
denaturation (94 °C for 1 min), annealing (55 °C for 1 min), extension (72 °C for 1 
min), and after the 30th cycle the extension was continued for a further 10 min at 72 
°C to ensure that the final extension step was complete. DNA of reference strain of 
C. botulinum type C or D as positive control and a negative control containing all of 
the reagents except template DNA were included in each PCR amplification. 
  
3.2.2.6 Gel electrophoresis 
Two percent agarose (MERCK) was used to visualize the PCR products. Agarose was 
boiled to dissolve in 1 x TBE buffer (89 mM Tris-base, 2 mM EDTA, and 89 mM boric 
acid per litre, pH 8.0). DNA fragments were made visible by adding ethidium bromide 
to a final concentration of 0.55 µg/ml of the molten agarose. 
 
Eighteen-microlitre portions of the resulting amplification reaction mixture were 
electrophoresed (BIO-RAD, USA). Standard DNA fragments (DNA molecular weight 
marker VI, FINNZYMES, Espoo) were used as molecular weight markers. Seven 
microlitres of the standard DNA were put into each raw in the gel. Positive controls 
were included in each raw and a negative control in one well per gel. Electrophoresis 
was carried out for 30 min at 75 V or 120 V for 1 h. The amplification products were 
visualized and photographed with a U.V. transilluminator (MWG-BIOTECH, Germany).  
 
To avoid contamination, sample preparation, PCR amplification, and electrophoresis 
were done in three different rooms.  
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3.2.4 Magnetic bead-ELISA  
Only 28 isolates were assayed by MB-ELISA for types C and D neurotoxins (the 
isolates which were neutralized by botulinum antitoxins type CD mixture with mouse 
bioassay). The isolates were grown in fFAB anaerobically at 37 °C for two or five 
days. Cultures were centrifuged at 4000 x g for 30 min and supernatants were 
assayed by an immunomagnetic assay based on enzyme-linked immunosorbent 
assay (MB-ELISA), developed by IBT, unpublished data. Monoclonal mouse-
antibody and polyclonal goat-antibody (biotinylated) against type C and D BoNTs 
were used as capture and detecting antibodies, respectively and to form toxin-
antibody complex; magnetic beads coated with sheep anti-mouse IgG, as secondary 
capture antibody, were added and presence of specific reactants was indicated by 
enzyme-substrate system (streptavidin-HRP-TMB).   
 
Procedure. Standard toxins, to serve as positive controls, were included in each test. 
The standard toxins were used as undiluted, 1:10, 1:100, and 1:1000 dilutions in 
GPB (pH 6.2). The test toxins were added as 1:10 in GPB and undiluted. The test 
and standard toxins were pipetted as 1.4 ml each into 4-ml-tubes (NEOLAB, 
Heidelberg). Then a biotinylated polyclonal goat-antibody (0.1µg/ml) and monoclonal 
mouse-antibody (0.3 µg/ml), specific for types C and D neurotoxins, were added and 
reactants were shaken by a rotatory shaker (VORTEX) at low speed overnight at 37 
°C. After incubation, 1.4 ml casein buffer (1.375 %, STREOSPECIFIC DETECTION 
TECHNOLOGIES (SDT), Germany) were pipetted into each tube and then 10 µl of 
dynabeads coated with sheep anti-mouse IgG (Dynabeads M-280, DYNAL BIOTECH, 
Oslo) were added. The tubes were shaken with a rotatory shaker with minimal speed 
for 1 h at RT. After incubation, the tubes were put into a magnetic particle 
concentrator (MPC-M, DYNAL) to separate the magnetic beads and the immune 
complexes to the tube side next to the magnet, and after 1 min the liquid part was 
aspirated from each tube. Then the tubes were released from the MPC-M and 1 ml 
casein buffer to each tube is added to wash excess or nonadsorbed reactants. Again 
the beads separated by the magnet and the liquid part discarded. The tubes were 
again released from the MPC and the magnetic beads were suspended into 200 µl 
casein buffer and the suspension was transferred to a top-yield-module (NUNC) 
blocked with 1 % BSA, which was put into a magnetic particle concentrator (MPC-96, 
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DYNAL). After 1 min, the liquid part was discarded, the module released from the 
MPC-96 and washed with 200 µl casein buffer. Washing was repeated four times, 
each time the beads were separated by the magnet and the liquid portion discarded. 
Streptavidin-HRP-80 (SDT), 1:2 in casein concentrate (5 %, SDT) was diluted to 
1:10,000 in PBS (pH 7.3) and 200 µl were pipetted into each well. The module was 
sealed with a sealing tape (NUNC) and put into a horizontal shaker (HEIDOLPH 
INSTRUMENTS, Schwabach) for 1 h at RT. Afterwards; the plate was washed three 
times with 200 µl casein buffer as before. The substrate solution was prepared by 
dissolving one tablet of TMB (3,3´-5,5´-tetramethylbenzidine [SIGMA-ALDRICH 
CHEMICALS]) in 1 ml DMSO (dimethylsulfoxide [SIGMA] and then 9 ml phosphate 
citrate buffer (pH 5.0) and 2 µl H2O2 (30%) were added. In parallel, the magnetic 
beads in the top-yield module were washed with 200 µl phosphate citrate buffer as 
before. After washing, 200 µl of substrate solution were added to each well and the 
module was put onto a horizontal shaker for 10 min at RT. After incubation, the 
module was put into MPC-96 and then 150 µl of supernatant were pipetted from each 
well into an immuno-polysorp plate (NUNC, Wiesbaden). Then a first reading of the 
absorbance, including 150 µl of substrate as blank, was read at 655 nm by Digiscan 
plate reader (ASYS HITECH, Austria). A second reading after stopping the reaction by 
addition of 50 µl of H2SO4 (25 %), was made at 450 nm. The absorbance reading of a 
well containing all the reagents except the toxin was considered as the cut-off value. 
A schematic drawing for the steps of this procedure is shown in Fig. 7. 
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Fig. 7:      Schematic drawing showing steps of MB-ELISA procedure  
1. Test and standard 
toxins (Ags) are added to 
4-ml tubes 
2. Biotinylated polyclonal 
goat-Ab & monoclonal 
mouse- Ab are added to Ags 
and slowly shaken overnight 
at 37 °C  
3. Dynabeads coated with 
sheep anti-mouse, and 
caseine buffer are added to 
Ag-Ab complex & tubes 
rotated for 1 h at RT
4. Magnetic separation of 
immune complex and 
aspiration of liquid part 
after 1 min 
5. Tubes are released from 
the magnet & immune 
complex suspended in 1 ml 
caseine buffer to wash 
nonadsorbed reactants
6. Magnetic separation of 
particles & aspiration of 
liquid part 
7. Tubes are released from 
the magnet & the immune 
complex suspended in 
200µl caseine buffer & the 
suspension is transferred to 
top-yield-module blocked 
with 1% BSA 
8. Immune complex in 
the wells of the module 
is separated & liquid part 
discarded 
9. The module is released 
from the magnet & 
washed 4x, each time 
particles separated before 
discarding of liquid part 
10. Addition of 
streptavidin-HRP, sealing 
of module & shaking for 1 
h at RT + washing 3x with 
caseine buffer & 1x with 
phosphate citrate buffer 
11. Addition of 
substrate solution & 
shaking for 10 min 
at RT 
12. Magnetic separation & 
transference of 150µl of 
supernatant to each well of 
an immuno-polysorp plate 
MPC-M 
 MPC-96
13. The absorbance of the  
supernatant in each well of 
 the plate is read by ELISA  
reader before & after stoppage  
of reaction by H2SO4 
= Toxins (Ags) 
= Substrate 
= Biotin. goat-Ab 
= Mouse-Ab 
= Streptav.-HRP 
=MB coated with  
sheep anti-mouse  
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3.3 Results  
 
3.3.1 Culture methods and isolation 
According to colony and cellular morphology, toxin neutralization, and molecular and 
immunological typing, the confirmed C. botulinum isolates in the current study are 
only four. Two of them are type C and the other two are type D. The two type C 
isolates were from intestinal contents of two broiler chickens from a farm with 
botulism outbreak; one of type D isolates was from intestine of a case of bovine 
botulism and the other from faeces of a rabbit experimentally infected with C. 
botulinum type D together with other bacteria. The colonial and cellular morphology 
of the three field isolates is shown in Table 4. The two type C isolates are similar in 
cellular and differ in colonial morphology. Both are short to long slender Gram-
positive rods with subterminal pulging spores, lipase-positive, β-haemolytic (human, 
but not horse blood) and both can swarm if the plates are not dry enough. The 
difference is that the colony of one of them is raised pyramidal with rhizoidal edge 
and the other is flat or slightly raised with rhizoidal edge (Fig. 15a and b). The colony 
of the bovine isolate type D is raised with uneven edge and cells are short to long 
slender rods with subterminal pulging spores (Fig. 15c). None of the four isolates was 
obtained after enrichment in liquid broth. Two of them were isolated after direct heat 
treatment, one after direct alcohol treatment and one by direct streaking. 
 
A large number of lipase-, lecithinase-, lipase-/lecithinase-positive or lipase-
/lecithinase-negative clostridia, and E. coli-like organisms were isolated. All the 
isolates were tested for toxicity and toxin neutralization by mouse bioassay and some 
of them by PCR and immunoassay (see below). Different clostridia-like colonies, as 
indicated by different colonial morphotypes and cellular morphology, were isolated.  
 
According to colony and cellular morphology of clostridia in the literature, the 
following clostridial species were most likely isolated: C. sporogenes, C. perfringens, 
C. tetani, C. novyi, C. bifermentans, C. septicum, C. tertium, C. ramosum and C. 
botulinum. Inspite of many C. botulinum-like isolates, only four were confirmed to be 
C. botulinum. Colonies and smears of some lipase and lecithinase positive 
Clostridium spp. are shown in Figs. 16a-b and 17a-b. It was observed that the types 
and numbers of clostridia are more in GS cases samples than in control samples. 
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Table 4:    Colonial and cellular morphology of confirmed field isolates of C. botulinum  
 
Colonial characteristics Cellular characteristics Isolate Source 
Growth Edge Surface Lipase Haemolysis Gram 
reaction 
Width Arrangement Spore Motility 
C. 
botulinum 
type C 
Chicken 
intestine
Localized (on dry 
plate), irregular 
raised pyramidal; 
swarming on less 
dried plate 
Rhizoidal Rough + β-haemolysis 
(human but not 
horse blood) 
+ Slender  Occuring 
singly, short - 
long rods  
Subterminal, 
oval, 
pulging 
+ 
C. 
botulinum 
type C 
Chicken 
intestine
Localized (on dry 
plate), irregular 
flat or slightly 
raised; swarming 
on less dried plate 
Rhizoidal Rough + β -haemolysis 
(human but not 
horse blood) 
+ Slender  Occuring 
singly, short - 
long rods  
Subterminal, 
oval, 
pulging 
+ 
C. 
botulinum 
type D 
Bovine 
liver 
Localized (on dry 
plate), irregular 
raised, swarming 
on less dried plate 
Uneven Rough + β -haemolysis 
(human but not 
horse blood) 
+ Slender Occuring 
singly, short to 
long rods  
Subterminal, 
oval, 
pulging 
+ 
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Why were lecithinase-positive and E. coli-like colonies isolated in this study? That 
because early in this study, an isolate of Gram-positive slender rods was picked from 
blood agar plate, i.e. at that time not known whether it is lipase-positive or negative, 
which was tested by bioassay and PCR and found positive for C. botulinum  type D; 
and later was confirmed to be C. perfringens by 16S rRNA. Also, because C. 
perfringens may has a role in the causation of EGS (Ochoa and de Velandia, 1978). 
A supernatant of enrichment broth culture of first GS sample investigated was 
neutralized by type CD antitoxins and when this culture was thoroughly investigated, 
the only toxic isolate was Gram-negative non-sporulating short slender rods and no 
lipase-positive colony found in this sample. This isolate was neutralized by type CD 
and then type C antitoxin and later was confirmed to be E. coli by 16S rRNA. Then 
afterwards, a number of lecithinase- and E. coli-like isolates were isolated and tested 
by bioassay and some of them were found toxic and neutralizable by botulinum 
antitoxins (details are shown below). Identification of E. coli isolates was partly done 
by inoculation of Gassner agar medium (MERK), on which the growth of E. coli 
changes the colour of the medium from green to dark blue. It was observed that 
some of the E. coli isolates if incubated for more than two days, their cells appear 
filamentous or much longer than normal. Colonies and smears of some lecithinase 
positive and E. coli are shown in Figs. 17a-d and 18a-d).    
 
From the initial study to select a medium to work with, fFAB and FAA media were 
found the best; depending on growth and toxicity of isolates. Also, the two media 
were compared with RCM (the standard medium used by the institute), BA (solid 
RCM with human blood) and EYA; inoculating reference strains of C. botulinm types 
A to F (Table 5). The growth was found better (larger colonies) on FAA than on BA 
and far better than on EYA; while the growth in fFAB at pH 6.8 and RCM was more 
or less the same. However, when FAB (without fortification, at pH 6.8 and 7.2) was 
compared with RCM, the growth in RCM was either better or the same as in FAB. 
The growth in FAB at pH 6.8 was better than at pH 7.2.  
 
To facilitate the isolation of clostridial colonies, heat test was used. However, the test 
for most samples was done not perfect as indicated by the colony and cell types after 
incubation. Different facultative and anaerobic cocci and non-spore formers bacilli 
were observed. Also, E. coli isolates were able to grow at 60 °C for 4 h and at 80 °C  
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for up to 30 min. This was because the inoculum, whether from liquid culture or from 
the specimen was transferred not cautiously into the medium down to the bottom of 
the tube (Holdeman et al., 1977; CDC, 1998), but always part of it may touch the wall 
of the tube. This was confirmed by inoculating E.  coli isolate into two liquid medium 
tubes; one of them in a way that part of the inoculum attached to the wall of the tube 
and the inoculum in the other tube was cautiously transferred into the medium. E. coli 
was able to grow at 80 °C for 10 min in the tube which was not properly inoculated 
and no growth in the other tube. This because the part of the inoculum attached to 
the tube wall above medium level was far less heated and later, due to water vapour 
or declining of the tube, it reached the medium and grew during the incubation 
period. To confirm this, two tubes containing liquid medium, one was put into a water 
bath with high level of water (near the top end of the tube) and the other in the water 
bath with lower level of water (just above the medium level in the tube). The set 
temperature was 80 °C. After enough time for the tubes to heat up, the temperature 
inside the tube at different distances above medium level was measured by 
introducing a calibrated thermometer inside each tube and the tubes were tightly 
closed with cotton wool (Fig. 8). The temperature was found decreasing from the 
medium level upwards in both cases of water level in the water bath. It was lesser in 
case of low level of water in the water bath and the temperature in this case near the 
top end of the tube was only 43 °C; a temperature at which E. coli can normally grow. 
Furthermore, this low temperature in this part of the tube is a dry heat which is less 
effective than moist heat to kill bacteria. 
 
Table 5: Growth of reference strains of C. botulinum* in FAB/FAA compared to 
 RCM/BA and EYA   
 
Medium 
 
C. botulinum type 
Name pH A B C D E F 
RCM  6.8 +++ +++ +++ ++ + +++ 
FAB  6.8 +++ +++ ++ + + +++ 
FAB  7.2 ++ ++ + + + ++ 
fFAB (+BH) 6.8 +++ +++ ++ ++ + +++ 
FAA  6.8 +++ +++ +++ ++ ++ +++ 
BA  6.8 ++ ++ ++ + + ++ 
EYA  6.8 + + + < + < + ++ 
 
* The strains tested were: 62A (type A), Okra (type B), 003-9 (type C), C3-16 (type 
D), CB-S-21E (type E) and 83-4304 (type F). 
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Also, to select for spore-formers, alcohol test was performed for a large number of 
samples. However, after the initial mixing of equal volumes of broth culture and 
ethanol, the mixture was not mixed again every 15 min as described by CDC (1998). 
So, several types of non-spore-formers were encountered by this method. Mixing 
every 15 min was found important to kill all vegetative forms. It seems if the mixture 
mixed only once, large number of cells will adhere to the side of the tube and after 
some minutes the ethanol will evaporate from the side of the tube and the cells 
attached to the wall will be less affected. As the mixture is centrifuged and the 
pelleted material is suspended in a washing solution to remove the alcohol, the less 
affected cells will be mixed again.  
 
 
 
 
 
During the isolation process, swarming growth was frequently observed on primary or 
subsequent plates. It was frequently observed that the swarming growth may not 
appear on primary plates, but found in the subsequent purification process. More 
than one type of swarming cells were seen in Gram stain, but the majority of cases 
are C. tetani-like cells (racket-shaped).  It was recommended to use phenyl ethanol 
at a concentration of 0.25 % in the plates to prevent the swarming character of some 
clostridia (Jousimies-Somer et al., 2002).  However, the swarming ability of the major 
type of swarming cells encountered (C. tetani-like) was not prevented by either 0.25 
Fig. 8.  Schematic drawing to show how the temperature inside the  
tube varies during heat test at 80 °C in the water bath 
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% or 0.375 % of 2-phenyl ethanol (PE) (SIGMA-ALDRICH CHEMICALS), but only by 0.5 
% concentration. Reference strains of C. botulinum were able to grow on 0.25 % but 
not on 0.5 % concentration of PE.  
 
Later to check for purity and toxicity, 14 of the isolates previously neutralized by 
botulinum antitoxins were found contaminated with C. tetani-like swarming growth, 
either on normal agar percentage (1.4 %) used for routine work or only on 1 % agar 
plates. 12 of them were lipase positive and 2 were E. coli-like isolates. The swarming 
growth was separated from each isolate and tested in mice together with the main 
isolates (results are shown below). The main isolates were apparently purified by 
using plates containing 0.5 % PE. The rest of the isolates, which were previously 
neutralized by botulinum antitoxins, were also investigated for contamination with C. 
tetani in moist and low agar percentage plates, but C. tetani was not detected in any 
of them. The isolates found contaminated with C. tetani are mainly from 
environmental samples (details are shown below). Swarming and discrete colonies 
and smears of C. tetani are shown in Fig. 19a-d. 
 
To see if gentamicin has no inhibitory effect to growth of C. botulinum, so as to be 
used in isolation agar medium to reduce the number of accompanying flora to 
clostridia in test samples (Garrett et al., 2002), it was used at a concentration of 10 
mg/l. Plates containing gentamicin together with control ones, were inoculated with 
reference strains of C. botulinum types A-F. The growth of all types, except F, was 
either completely or partially inhibited by gentamicin, compared to growth on control 
plates. 
 
3.3.2 Mouse bioassay  
Out of 288 samples investigated, toxins of 53 isolates from 49 samples (17 %) were 
neutralized by polyvalent botulinum antitoxins, either type ABE (19 isolates), CD (33 
isolates) or by both ABE and CD (one isolate). Some of them were further splitted 
into single toxin types (Table 6). Distribution of these isolates according to their 
sample type has been shown in Tables 7 and 8. Out of the 53 neutralized isolates, 27 
were from GS samples (24 from GS cases samples and 3 control samples, Table 7). 
The neutralized isolates are either lipase-positive clostridia (23), lecithinase 
-positive clostridia (23) or E. coli isolates (7).  
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Table 6: Results of toxin neutralization test of isolates 
 
EGS samples (British) Non-EGS samples Toxin 
neutra- 
lization 
Lipase 
+ve 
Lecithinase 
 +ve 
E. coli-like Total Lipase
+ve 
Lecithinase 
+ve 
Total 
Total 
A 0 0 0 0 1 0 1 1 
 
B 3 0 0 3 2 0 2 5 
 
ABE 1 6 0 7 3 3 6 13 
 
C 0 0 3 3 2 1 3 6 
 
D 4 0 0 4 2 2 4 8 
 
C/D 1 1 0 2 3 1 4 6 
 
CD 0 3 4 7 0 6 6 13 
 
ABE/CD 1 0 0 1 0 0 0 1 
 
Total 10 10 7 27 13 13 26 53 
 
 
 
 
When toxin neutralization results of the isolates were compared with the results of 
their corresponding samples, which were obtained from the records of the routine 
standard diagnostic work of the institute (Table 3), the following was observed. The 
direct or after enrichment neutralization tests of samples showed that 77 (26.7 %) 
samples were neutralized by either polyvalent botulinum antitoxin type ABE (24), CD 
(38) or by both ABE and CD (19) (four of these samples showed different 
neutralization results by direct and after enrichment). Out of these neutralization 
results, 39 were from direct testing and 42 after enrichment (17 samples were heat-
treated). British GS samples had only nine (4.8 %) results from direct testing, while 
non-EGS samples had 25 (32.9 %). Comparing this with the neutralization results of 
the isolates (Table 6), only 17 % of samples had neutralizable isolates and the 
agreement between the two results was shown by only 16 samples, 13 of which were 
neutralized by type CD in both cases and three by ABE antitoxin. 
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Table 7:      Distribution of neutralized isolates of EGS samples according to sample type 
                 
GS samples Control samples Toxin neutralization results   Sample 
type* Lipase 
+ve 
Lecithinase
+ve 
E. 
coli 
total Lipase 
+ve 
Lecithinase
+ve 
E. 
coli 
Total ABE CD C D C/D B ABE/CD 
Stomach  1  1     1       
Jejunum  2  2     1 1      
Ileum  3 1 4   1 1 1 1 2a  1   
Caecum   1 1       1     
Colon      1  1 1       
Rectum       1 1  1      
Liver  2 1 3     1b 2      
Spleen  1  1     1       
Faeces 2   2          2  
Worm 
casts 
4   4     1   2 1   
Unidentif-
ied plant 
1   1        1    
Soil 1   1          1  
Mud 1  2 3      2a  1    
Grass 1   1           1 
Total 10 9 5 24 0 1 2 3 7 7 3 4 2 3 1 
 
*The GI tract samples were tissue and/or contents, aE. coli isolate, blecithinase-positive isolate  
 
 
Table 8:       Distribution of neutralized isolates of non-EGS samples according to 
                    sample type 
     
No. of isolates Toxin neutralization results Sample 
type Lipase +ve Lecithinase +ve Total ABE CD C/D A B C D 
Bovine 
small 
intestine 
2 4 6 1* 2   1*  2 
Bovine 
large 
intestine 
2  2   1 1    
Bovine 
liver 
1 3 4 2 1     1* 
Bovine 
faeces 
1 1 2 1 1      
Horse 
faeces 
2 2 4 1 1 1  1   
Chicken 
intestine 
2  2      2  
Rabbit 
faeces 
1  1   1     
Soil 2 3 5 1 1 1   1 1 
Total 13 13 26 6 6 4 1 2 3 4 
 
*Lipase-positive isolates 
 
 
Later to check purity and toxicity, 14 of the isolates previously neutralized by 
botulinum antitoxins were found contaminated with C. tetani-like swarming growth. 12 
of them were lipase positive and 2 were E. coli isolates. C. tetani-like growth from 
nine isolates, after being separately isolated were tested and found toxic in mice 
(supernatant and filtrate [0.2 µm])  and all of them were neutralized by tetanus 
antitoxin (Tetagam®N, AVENTIS BEHRING). Six of them were tested by polyvalent 
botulinum antitoxins types ABE and CD and all were neutralized by both antitoxin 
types at different dilution rates. Furthermore, some of them were neutralized by other 
types of botulinum antitoxins (Table 9). A 15th isolate showed slight swarming or 
spreading characteristic and the cells are not typical for C. tetani (with subterminal 
spores), but also neutralized by tetanus antitoxin. Another three out of four new C. 
tetani-like isolates also were found positive by both tetanus and botulinum antitoxin 
(types ABE and CD) and the fourth one was not tested. Some of the isolates found 
contaminated with C. tetani, after being apparently purified by using plates containing 
0.5 % PE, were found toxic and some not toxic. Most of the other neutralized 
isolates, which were found to be not contaminated with C. tetani, lost their toxicity. 
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Distribution of C. tetani isolates according to source and sample type is shown in 
Table 10. The tetanus antitoxin used, Tetagam®N, which is a human tetanus 
immunoglobulin was found potent enough to neutralize the C. tetani toxin even 
without dilution. It was observed that if mice were injected with diluted supernatant of 
tetanus toxin (1:100), the paralysis seen in hind limbs in the limb corresponding to the 
side of injection whether the left or the right side, but if not or less diluted, the 
paralysis is in both limbs. 
 
Table 9: Cross-reactions shown by C. tetani isolates* against C. botulinum 
antitoxins 
 
Number of isolates Source of isolates Type of 
C. botulinum 
antitoxin  
Tested Positive Negative EGS cases 
samples** 
Non-EGS 
samples 
 
CD (SA) 
 
10 
 
10 
 
0 
 
6 
 
4 
 
ABE  
 
7 
 
6 
 
1a 
 
 
5 
 
2 
CD (NL) 5 1b 4 
 
4 1 
A (NL) 6 3c 3 
 
5 1 
B (NL) 6 1b 5 
 
5 1 
E (NL) 5 1b 4 
 
4 1 
A (Russia) 2 2b 0 
 
2 0 
B (IBT) 7 0 7 
 
6 1 
E (IBT) 5 1b 4 
 
4 1 
F (USA) 6 2b 4 5 1 
 
SA= South Africa, NL=Netherlands   
*All the C. tetani isolates tested by tetanus antitoxin (12 isolates) were positive. 
**No toxic C. tetani was isolated from control samples. 
aOne isolate (EGS) tested negative by ABE because the test carried at low dilution 
(1:4) and it was observed that if the test carried at low toxin dilution rate, either CD or 
ABE tests positive, but if more diluted then the toxin is neutralized by both CD and 
ABE antitoxins. bEGS isolate, ctwo of them were EGS isolates. 
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Table 10: Distribution of C. tetani isolates* according to source and sample type 
 
Source Sample type No. of isolates 
Faeces 2 
Mud 4 
Worm casts 5 
Soil 1 
 
 
EGS cases samples 
Unidentified plant 1 
Bovine small intestine 2 
Bovine colon 1 
Bovine faeces 1 
Horse faeces 1 
 
 
Non-EGS samples 
Soil 1 
 
*All isolates (19) were found toxic, but not all tested by botulinum and tetanus 
antitoxins (details in table 9) 
 
Among the neutralized isolates, seven were E. coli isolates (all from GS samples) 
and 23 were lecithinase-positive isolates (Table 6). Their source and sample types 
are shown in Table 7. These isolates were checked for contamination with C. tetani 
or C. botulinum but only two of E. coli isolates were found contaminated with C. tetani 
that was found neutralizable by botulinum antitoxins. One of the lecithinase-positive 
isolates (from bovine intestine) was neutralized by two different types of botulinum 
antitoxin type D as well as it was also positive for type D by PCR. This isolate was 
identified by 16S rRNA as C. perfringens. Also, one of the E. coli isolates was 
neutralized by two different types of botulinum antitoxin type C. Colonies and smears 
of these two isolates are shown in Figs. 18a-d and 20).    
 
To see if any of C. botulinum toxins can be neutralized by the tetanus antitoxin used, 
toxin of reference strains of C. botulinum types A, B and C were tested as diluted 
supernatants (1:00), but none of them was neutralized. Other types were not tested. 
  
3.3.3 Polymerase chain reaction 
All the isolates showed positive toxin neutralization by mouse bioassay were tested 
by PCR according to the methods shown above. Non-toxic isolates were not tested.  
The isolates neutralized by type CD antitoxin mixture were tested by PCR for 
presence of BoNT/C and BoNT/D genes. Likewise, the isolates neutralized by type 
ABE polyvalent antitoxin were tested by PCR for presence of BoNT/A, B, E and F 
genes. PCR results showed specific products for type C in only three isolates and 
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specific products for type D for other three isolates (Table 11). None of the isolates 
neutralized by ABE yielded a PCR product. To test for the inhibitory effect of other 
bacteria to C. botulinum, bovine, equine and human faecal samples were each 
inoculated into liquid medium together with a reference strain of C. botulinum type A, 
B or C. Only type A was isolated and gave positive result by PCR. Isolation as well as 
enriched broth culture for types B and C were negative in PCR. C. tetani isolates 
showed no product in PCR. Photos of gel electrophoresis for PCR products of 
positive isolates are shown in Figs. 9-13. Two of the three isolates positive for type C 
toxin gene were isolated from intestinal contents of broiler chickens from a farm of 
botulism outbreak and the third from intestinal contents of a case of suspected bovine 
botulism. Besides being positive by bioassay, the two chicken isolates were also 
confirmed by MB-ELISA and their phenotypic characteristics were similar to C. 
botulinum. However, the third isolate (faint band) was lipase-negative and 
lecithinase-positive and due to this phenotypic character, which is unlike C. 
botulinum, it was retested by PCR and found negative and also negative by MB-
ELISA. Two of the three isolates positive for type D toxin gene were isolated from 
intestinal contents of two cases of bovine botulism and the third from faeces of a 
rabbit experimentally infected with C. botulinum type D together with other bacteria.  
 
 
Table 11:      Isolates positive by PCR  
 
No. of positive isolates 
 
 
C. 
botulinum 
type 
Lipase 
+ve 
Lecithinase 
+ve 
Total 
 
Source of isolates 
 
Remarks 
C 2 1 3 Chicken intestine 
(two, lipase +ve), 
bovine intestine 
(one) 
The result of the 
lecithinase positive 
isolate was not 
reproduced 
D 2 1 3 Bovine liver, bovine 
intestine 
(lecithinase +ve), 
rabbit faeces  
The result of the 
lecithinase positive 
isolate was not 
reproduced 
 
 
One of the two bovine isolates was lipase-negative and lecithinase-positive and due 
to this dissimilar character to C. botulinum, it was retested by PCR and found 
negative.   
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Later, DNA identification of this isolate was 100% complying with C. perfringens. 
Negative and positive controls in different PCR amplifications reacted accordingly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1           2           3          4          5           6          7           8        9           10       11        12         13       14         15
Fig. 11. PCR detection of C. botulinum type D. Lane 1, standard DNA 
marker; lanes 2 & 15, positive control; lane 4, negative control; lanes 
7 & 14, isolates (bovine liver and rabbit faeces, respectively).  
 
  
Fig. 9:   PCR detection of C. botulinum type C. Lane 1, standard DNA marker; lane 
2, positive control; lane 3 & 4, isolates from two intestines of broiler 
chickens; lane 6, negative control. 
 
 
 
 
Fig. 10:  PCR detection of C. botulinum type C. Lane 1, standard DNA marker; lane 
2, positive control; lane 14, bovine intestines isolate (lecithinase +ve);  lane 
15, negative control. 
 
    1               2               3              4               5               6  
 1          2          3           4          5           6        7         8         9        10       11       12        13        14        15
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3.3.4 Magnetic bead-ELISA 
The isolates tested by MB-ELISA were only 28, from those neutralized by type CD 
botulinum antitoxin mixture by bioassay. Only three isolates had positive results (Fig. 
14); two type C and one type D. The two type C isolates were chicken isolates and 
the type D isolate was from a rabbit artificially infected (Table 12). 
  
Table 12: Isolates positive by MB-ELISA  
Botulinum 
serotype 
No. of positive 
isolates 
Source of isolates Remarks 
C 2 Chicken intestine  Lipase positive, field 
samples 
 
D 1 Rabbit faeces  Lipase positive, 
experimental infection 
 
Fig. 12:    PCR detection of C. botulinum type D. Lane 1, standard DNA  
marker; lane 3, bovine intestine isolate (identified by 16S rRNA  
as C. perfringens); lane 8, positive control; lane 9, negative control.  
 
 
  
Fig. 13.  Multiplex PCR detection of C. botulinum. Lane 1, standard DNA 
marker; lanes 2 & 9, positive control (types A, F, E & B resp.); lane 5, 
type A isolated from a sample artificially infected; lane 10, negative 
control. 
       1               2                3              4                5             6              7               8                 9 
      1                 2               3               4                5              6                7               8               9             10
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Fig  14: MB-ELISA result. The photos showing the picture of microtitre plate and its absorbance readings. 
Top, the plate and absorbance reading at 655 nm before stoppage of reaction; and down, the plate 
and absorbance reading at 450 nm after stoppage of reaction. Columns: 2, positive control type D 
(diluted 10-2-10-6); 4, positive control type C (diluted 10-1-10-5); 6, isolates (diluted 10-1). Wells: A6 & 
B6, one of the two type C isolates (two broth cultures incubated for 2 & 5 days respect.); C6, the 
other type C isolate; D6, the bovine type D isolate (its reading is < negative control) ; E, rabbit 
isolate; and G4, negative control. 
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4 DISCUSSION 
 
 
4.1 Culture methods and isolation  
Inspite of the nearly ubiquitous distribution of C. botulinum, especially in soil samples 
(Whitlock and Buckly, 1997), the sound diagnosis of botulism (in case of some test 
samples in this work) and the several reports of evidences that associated C. 
botulinum with the EGS (Tocher et al., 1923; Hunter et al., 1999; Böhnel et al., 2003), 
in the current study only four isolates from 288 test samples were confirmed to be C. 
botulinum. Natural intestinal and environmental conditions are impossible to be 
simulated in vitro (Smith and Sugiyama, 1988; Seifert and Böhnel, 1995). In nature, 
the toxico-infectious form of botulism in humans and horses was reported to occur 
mainly in neonates and rarely in adults after a predisposing factor (Chia et al., 1986). 
This is because adults, unlike infants and foals, have mature intestinal microflora, 
which can compete with C. botulinum and prevent its colonization (Arnon et al., 1978; 
Bartlett, 1986). This fact may strongly support the belief that the main reason behind 
the difficulty to isolate C. botulinum, seems to be due to its inhibition by other bacteria 
(Graham, 1978; Szabo et al., 1994; Sandler et al., 1998; Böhnel and Lube, 2000). 
Some reports showed that C. perfringens and C. tetani are examples of these 
inhibitory bacteria (Smith, 1975: Smith, 1978). Also, in this study, C. botulinum types 
A, B and C were inoculated, as 1 ml 48 h broth culture, each together with faecal 
material, which was negative for C. botulinum and its toxin; in liquid medium and 
incubated anaerobically at 37 °C for two and five days. Both isolation and PCR for 
primary broth culture were negative for both types C and B and positive for type A. 
The sample inoculated with type C contained C. tetani (isolated and its toxin 
neutralized by tetanus antitoxin) and the sample inoculated with type B contained C. 
perfringens- and C. tetani-like cells. This confirmed the inhibitory effect of other 
bacteria. The inhibitory bacteria seem to be widely distributed in field samples 
investigated in this study. Also, the isolation results in this study clearly demonstrated 
the inhibitory effect of other microflora on growth of C. botulinum.  Isolation of C. 
botulinum after enrichment in liquid medium was found hopeless. The four confirmed 
C. botulinum isolates were obtained either by direct streaking, after direct heat or 
alcohol treatment. Isolation of C. botulinum requires experience and proper selection 
and performance of technical methods; this was partly not fulfilled in this work. For 
example, direct streaking, direct heat or alcohol treatment, serial transfer of liquid 
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culture to increase few numbers of C. botulinum organisms (Segner et al., 1971), 
incubation for long time (5-7 days), picking of several lipase positive colonies 
because some isolates may be non-toxic (CDC, 1998), were either not done or 
improperly performed. C. botulinum, with exception of some strains of group III, is a 
strict anaerobe (Kriek and Odendaal, 1994). The samples of this study were 
transported, stored and processed in aerobic conditions; this exposure to oxygen 
may have adverse effect on viability and toxicity of C. botulinum. However, C. 
botulinum types A and B cultured in association with avian skin flora had similar 
growth patterns under both aerobic and anaerobic conditions (Dezfulian, 1999). This 
may be due to the reduced oxygen tension and low oxidation-reduction potential 
provided by the avian flora; but it is unlikely to say that strict anaerobic condition was 
achieved. Similarly, FIRSTENBERG et al. (1982) found that C. botulinum type E was 
able to grow and produce toxin in aerobic condition. The EGS samples were stored 
at -80 °C for long time; so, the viability of vegetative forms might be affected by deep 
freezing (CDC, 1998; Jousimies-Somer et al., 2002). This may partly be shown by 
the observation that most of the toxin neutralization test results in this study were 
obtained early after the beginning of the work. Moreover, C. botulinum can lose its 
toxicity during isolation process (Collins and East, 1998) or naturally it may not 
always be toxic (Galey, 2001), perhaps helping to explain the sporadic nature of the 
outbreaks and hence, some of non-toxic lipase-positive colonies could be C. 
botulinum. In addition, the presence of similar lipase positive colonies in a plate was 
sometimes represented by picking one colony, which may be not the target one, if 
present; however, this is unlikely to be always the case. Isolation of C. botulinum, 
including type C was found not impossible (Segner et al., 1971, Hatheway and 
McCroskey, 1987); however, in this study no single confirmed C. botulinum was 
isolated from EGS. This negative isolation result may also be contributed to the 
extreme sensitivity of horses to botulism (Galey et al., 2000), a case in which number 
of bacteria in the animal samples may be too low to be isolated. As C. botulinum is 
almost ubiquitous and can be found normally in soil and possibly in GI tract of horses 
(Ricketts and Greet, 1984), the isolation results of EGS samples were of many false-
negatives, despite the possibility of isolation of some non-toxic C. botulinum. 
However, these results could show that C. botulinum is at least not prevailing in GS 
samples and its association with the disease remains doubtful.  
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According to colony and cellular morphology, several Clostridium species were 
isolated (see results). Their types and numbers in GS samples were obviously 
greater than in control samples. This was in agreement with the findings of GRIEß et 
al. (1996) and GARRETT et al. (2002). The high presence of clostridia in GS cases 
more than in controls may be due to the stasis or change in the ecology of GI tract of 
diseased animals or dropage of local immunity (Garrett et al., 2002). C. perfringens, 
C. tetani and C. sporogenes are possibly most isolated.  C. perfringens was 
frequently isolated from GS samples, especially from animal samples. It was isolated 
from all samples tested from two cases of EGS; one of them is a case artificially 
infected by a suspected soil in Dubai. The samples of these two cases were 
thoroughly investigated for presence of C. botulinum and found negative. Also, E. coli 
and C. tetani were isolated from GS cases more than from control ones and some of 
their isolates were neutralized by botulinum antitoxins. So, a direct or indirect role to 
C. perfringens, C. tetani and/or E. coli is not unexpected.  
 
The swarming growth frequently encountered in plates, especially C. tetani, was one 
of the problems that may contribute to failure of isolation of C. botulinum, either 
preventing its growth or found very difficult to be separated from the swarming 
bacteria. JOUSIMIES-SOMER et al. (2002) recommended the usage of phenyl 
ethanol to combat the swarming growth of some clostridia at a concentration of 0.25 
%. However, in this study, the swarming character of C. tetani was not prevented by 
0.25 % and 0.375 % and prevented by 0.5 %. Besides the growth of all types of C. 
botulinum was completely inhibited by PE at a concentration of 0.5 % and slightly 
affected at a concentration of 0.25 %. So, the usage of PE could be only in case of a 
lipase positive colony was picked from a plate with swarming growth or later found 
contaminated with other swarming bacteria, but not in the primary plates as it will 
prevent the growth of C. botulinum at the concentration required to inhibit C. tetani 
(0.5 %). The swarming growth may not appear in the primary plates; due to less 
moisture or effect of other bacteria, but appear in the subsequent plates during the 
purification process or only after an apparently pure colony being grown into liquid 
medium and then cultured on solid medium. Phenyl alcohol acts by inhibiting 
flagellation and thereby prevents swarming (Sharma and Anand, 2002). Also it can 
prevent growth of facultative Gram-negative rods. The critical factors that determine 
whether the cells swarm or form regular colonies are: the concentration of agar, 
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surface moisture and viscosity (Sharma and Anand, 2002). Some Clostridium 
species are able to form swarming colonies on the surface of 2 % agar plates 
(Sharma and Anand, 2002) and in this study C. tetani was able to swarm on 3 % agar 
plates if not well dried and sometimes not on 1.4 % agar plates if well dried. So, it 
seems the degree of dryness is more critical than percentage of agar. However, 
reduced surface moisture is not very reliable as the dryness required to inhibit 
swarming would completely suppress the growth of fastidious organisms (Sharma 
and Anand, 2002). This was in agreement with HERNÁNDEZ-CHAVARRÍA et al. 
(2001), who used plates with 4% agar to have discrete colonies of C. tetani. C. tetani 
is just second to Proteus mirabilis in the rate of surface translocation (Sharma and 
Anand, 2002).  Other Clostridium species that can swarm are C. sporogenes, C. 
novyi, C. bifermentans, C. septicum, C. butrificum, C. fallax, C. glicolicum, C. 
haemolyticum and C. beijerinkii (Hernández-Chavarría et al., 2001; Sharma and 
Anand, 2002; Jousimies-Somer et al., 2002). It was not found reported that C. 
botulinum can swarm; however, in this study two type C and one type D C. botulinum 
isolates were able to swarm. C. novyi type A, the related Clostridium to group III C. 
botulinum (Eklund and Poysky, 1994), is known of its swarming character (Sharma 
and Anand, 2002). So, likely other members of group III (C. botulinum types C and D) 
or some of their strains, which are not yet isolated, could swarm. It is known that 
group III members can be converted to each other if infected by the specific phage in 
vitro, which was also thought to occur in nature (Eklund and Poysky, 1994); so, less 
likely, these type C and D isolates may be C. novyi type A strains naturally infected 
by type C and D specific phages. Thus, swarming growth should be tested for C. 
botulinum.  
 
The agar medium used in this study (FAA) was found the best, compared to BA and 
EYA, to encourage growth of Clostridium spp., including C. perfringens, C. tetani and 
reference strains of C. botulinum. However, its broth, compared to RCM, was not 
better and the reason for that is difficult to show. One may say that isolation of C. 
botulinum is possible by direct streaking on FAA plates, and application of direct heat 
and alcohol treatment. However, the easy isolation of C. botulinum is still waiting for a 
highly selective medium for all groups of C. botulinum.  
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4.2 Mouse bioassay 
A total of 53 isolates had positive toxin neutralization results. These isolates were 
either lipase-positive, lecithinase-positive clostridia or E. coli. Only four of them 
(lipase-positive) were confirmed to be C. botulinum by other diagnostic means. Later, 
some of them were found contaminated with C. tetani, which was proved to be the 
cause of their false-positive results; and no C. tetani contamination was seen with the 
other ones, which were tested again and most of them found not toxic. Why most 
isolates that showed positive neutralization results became non-toxic, may be 
attributed to the following. Mainly attributed to false-positive results due to non-
botulinum lethalities, which their avoidance was not considered in this work; or to low 
level of contamination with C. botulinum which was later disappeared. This was partly 
confirmed in case of many isolates found contaminated with swarming C. tetani, 
which was isolated and found neutralizable by different botulinum antitoxins (Table 9) 
and one isolate (lecithinase-positive) found contaminated with swarming C. 
botulinum. In addition, the lipase-positive isolates or part of them may be C. 
botulinum but their toxicity was lost as it was reported that pure C. botulinum isolates 
may lose toxicity (Eklund et al., 1971). Seven E. coli isolates (all from GS samples) 
and 23 lecithinase-positive isolates (ten from GS samples) were found neutralizable 
by botulinum antitoxins. Five of the E. coli isolates were from GS cases samples and 
two from control samples and nine of the lecithinase-positive isolates (most of them 
look like C. perfringens) were from GS cases samples and one from control samples. 
When these isolates were investigated for contamination with C. botulinum or C. 
tetani, only two (E. coli isolates) were found contaminated with C. tetani. Interestingly, 
two of them (one lecithinase-positive and one E. coli-like isolate) were neutralized by 
two different types of botulinum antitoxin type D and C respectively, and the 
lecithinase-positive isolate was also positive for BoNT/D gene by PCR. They were 
thoroughly investigated for contamination by either C. botulinum or C. tetani but 
found pure. These two isolates were then confirmed to be C. perfringens and E. coli 
(16S rRNA). Such results could be attributed to a non-isolatable level of 
contamination by C. botulinum or C. tetani in case of the isolates other than the 
confirmed two isolates or to some gene transfer which was then lost. Nineteen C. 
tetani islolates (14 of them found as contaminant with other isolates) were found toxic 
and some of them were tested by tetanus and botulinum antitoxins and all found 
neutralizable. Thirteen of them were from GS cases samples and no toxic isolate 
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from control samples. It was observed that E. coli and C. perfringens-like isolates 
were mostly from animal and not environmental samples and C. tetani isolates were 
from environmental samples. These findings may strongly suggest a role to one or 
more of these three species in the causation of EGS either directly or indirectly. 
 
The neutralization results of non-botulinum isolates or at least part of them indicate 
that mouse bioassay is non-specific and questionable. Many false-positive results 
were confirmed to be due to cross-reactions between botulinum and tetanus toxins. 
C. tetani is a normal inhabitant of soil (Smith, 1978), so results from soil samples 
should be checked for tetanus toxin. Other non-botulinum lethalities such as 
endotoxins of Gram-negative bacteria also may have a role in these results. In 
general, the mouse bioassay was claimed to be not suitable for examination of test 
samples containing other lethal substances (Dezfulian and Bartlett, 1985). To avoid 
or reduce the effect of lethalities other than botulism in the bioassay, high 
centrifugation and/or filtration of liquid culture (Solomon and Lilly, 1998), treatment of 
supernatants by overnight deep freezing (Smith and Sugiyama, 1988), dilution of 
supernatants (Hatheway and McCroskey, 1987), addition of BSA (Solberg et al., 
1985), use of antibiotics (Sandler et al., 1993), and preinjection of antitetanus (Smith 
and Sugiyama, 1988), were indicated. It was observed that a sample may be 
neutralized by both ABE and CD antitoxins; this was shown possible in case the 
sample containing tetanus toxin, but not possible in case of a botulinum toxin, as 
group I or II toxins were not reported to cross-react with group III toxins. Also, not 
possible in case of existence of more than one toxin type from these groups, as the 
neutralization in this case will happen only if ABE and CD antitoxins were mixed 
together. Tetanus toxin in this study was shown to cross-react with different 
botulinum antitoxins (Table 9). Toxins of all C. tetani isolates tested were neutralized 
by both ABE and CD at different dilutions. However, results of other antitoxins were 
not repeated to see whether the results are reproducible or not. Tetanus toxin may 
cross-react with BoNT/B and A (Dolimbeck et al., 2002), but cross-reactions with 
other BoNTs may not be reported. However, at least part of these results could be 
attributed to the quality of the antitoxin used. For example, all supernatants tested by 
CD (SA) or ABE (AVENTIS BEHRING)  had positive results, while none of seven 
supernatants tested by type B antitoxin of IBT (raised in chickens) had positive result. 
So, type and specificity of the proteins of the toxoid and/or the animal species from 
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which these antisera were obtained may have an effect. To see if BoNTs can be 
neutralized by tetanus antitoxin, toxins of the reference strains types A, B, and C 
were tested; but none of them was neutralized. However, cross-reaction between 
botulinum toxins types A and B with tetanus toxin was reported by DOLIMBECK et al. 
(2002).  
 
The samples of this work were all tested for presence of BoNTs by the standard 
mouse bioassay either directly or after enrichment by the institute (Table 3). When 
the neutralization result of the institute were compared with the neutralization result of 
the isolates in this study to see how the results agree with each other, the following 
was observed. Evidence of BoNT was shown in 26.7 % (77/288) of all samples and 
in 19.3 % (36/187) of GS samples compared to neutralizable isolates from 17 % 
(49/288) of all samples and 14.4 % (27/288) of GS samples. The apparent 
agreement between the two results was shown by only 16 samples, 13 of which were 
neutralized by type CD in both cases and three by ABE antitoxin. This low agreement 
could be partly attributed to the low isolation rate (from 49 samples compared to 77 
samples showed evidence of BoNTs) and to non-specific results especially due to 
tetanus toxin which was proved in this study that it can be neutralized by ABE, CD or 
both according to its concentration in the test supernatant. This may be supported by 
the observation that 19 of the 77 samples were neutralized by both ABE and CD, 
which is not expected in case of BoNT as none of types A, B or E was reported to 
cross-react with either type C or D. One interesting observation is that only 4.8 % 
(9/187) of GS samples had evidence of BoNT from direct testing compared to 32.9 % 
(25/76) of non-EGS samples. This may indicate that the presence of BoNT is not 
prevailing in these samples or may be due to the extreme sensitivity of the horse it 
exists but in a non-detectable level.   
 
4.3 Polymerase chain reaction 
PCR assays were performed to test for BoNT genes (A-F) in all the isolates which 
gave positive results by the mouse bioassay (Table 6). Only six isolates yielded PCR 
products. The products of three of them were specific for type C and the products of 
the other three were specific for type D. Two type C and two type D isolates were 
culturally similar to C. botulinum. However, the third type C and type D isolates were 
culturally dissimilar to C. botulinum; both were lipase-negative and lecithinase-
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positive. The type D isolate was phenotypically and genotypically (16S rRNA study) 
identified as C. perfringens. This isolate was neutralized by two different type D 
antitoxins by the bioassay. Both type C and type D isolates were thoroughly 
investigated for contamination with C. botulinum, but not detected. Later, both of 
them lost their toxicity and their PCR result was not reproduced. These unexpected 
two results can be attributed mainly to the following. 1) Very low level of 
contamination with C. botulinum from the sample of the isolate; however, this may be 
possible in case of type C isolate but not type D isolate as it was 100% identified as 
C. perfringens by 16S rRNA study. C. botulinum, in this study, was found can swarm 
and its swarming growth can be in a very thin layer that could not be detected by 
naked eye. So, if a plate with apparently only one type of colony, after subculture in a 
liquid broth, the contaminant could appear. This was confirmed by one of type D 
isolates, which was a lipase-negative and found positive for type D by PCR. This 
isolate was investigated for contamination with C. botulinum, which was found as a 
very thin layer of swarming growth. 2) Detection of C. botulinum type B gene in two of 
C. subterminale cultures was reported (Franciosa et al., 1994); C. baratii, C. 
butyricum and C. argentinense are phenotypically different from all C. botulinum 
strains, but are known to produce BoNTs (Collins and East, 1998); organisms of 
group III C. botulinum (type C, D, and C. novyi type A) can be converted to each 
other, both in nature and in vitro, if infected by the specific phage (Eklund and 
Poysky, 1994). These reports may indicate that these two results or one of them 
could be due to some gene transfer from C. botulinum or a mutation happened in 
nature to these isolates. 3) Other factors such as molecular contamination with DNA 
from the reagents used or during preparation of template or afterwards, are not totally 
excluded. However, to avoid contamination, sample preparation, PCR amplification, 
and electrophoresis were done in three different rooms.  
 
Compared to the results of immunoassay, PCR is considered more sensitive. The 
immunoassay did not detect a low level of contamination by C. botulinum in one 
isolate, which was detected by both PCR and bioassay. Also, when C. botulinum was 
purified from this isolate, it was found positive by both bioassay and PCR and not by 
immunoassay. In addition, PCR had two more results for dissimilar C. botulinum 
isolates, at least one of them may be due to very low level of contamination with C. 
botulinum. However, due to these last two results, it may be less specific. Compared 
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to isolation and bioassay, PCR is considered less sensitive. It showed at least one 
false-negative result, compared to the isolation; and many, compared to the 
bioassay. A type D isolate from a faecal sample of a rabbit experimentally infected 
with type D together with other bacteria, was isolated from a broth culture found 
negative by PCR. This isolate was then tested positive by both PCR and 
immunoassay. Most of the mouse bioassay results were found false-positive and no 
confirmation that bioassay was more sensitive than PCR. False-negative results by 
PCR could be attributed to factors such as inhibitory substances in the media 
(Ferreira et al., 1993). Within the type D strains neurotoxins differ in molecular 
structure and antigenicity (Moriishi et al., 1989), so, the primers may have an effect 
(Campbell et al., 1993), template preparation method which can affect DNA isolation 
in good quality (Szabo et al., 1994a), and DNA concentration (Fach et al., 2002) and 
purification (Williamson et al., 1999) may also have an effect. 
 
4.4 Magnetic bead-ELISA 
Out of 28 isolates, which were positive by bioassay for type C, D or both botulinum 
toxins, only three had positive results by MB-ELISA. False-positive results by ELISA 
were reported (Potter et al., 1993) due to the reaction of capture antibodies with non-
toxigenic haemagglutinin molecules produced along with the toxin, or capture 
antibodies reacted with a somatic antigen or other protein produced by the organism. 
However, this immunoassay is considered 100% specific, compared to both bioassay 
and PCR performance. Sensitive immunoassays, unlike the mouse bioassay can 
detect the toxin either in active or inactive form, or in a level below mouse sensitivity. 
However, this MB-ELISA assay showed at least one false-negative result, compared 
to both bioassay and PCR. Three isolates (lecithinase-positive) were positive by both 
bioassay and PCR and none of them was positive by MB-ELISA, but only one was 
proved to contain C. botulinum. When C. botulinum was separated from this isolate, it 
was also found positive type D by both bioassay and PCR and negative by MB-
ELISA. This isolate is also culturally similar to C. botulinum and showed the classic 
botulism signs in mice. This false-negative result may be because the antigenecity of 
the toxin of the strain used to raise the antibodies used in this assay is different from 
that of this isolate. It was found that within the type D strains, neurotoxins differ in 
molecular structure and antigenicity (Moriishi et al., 1989). Also, the absorbance 
reading of this isolate was much higher than the expected readings for negative 
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isolates; thus the cut-off value for this assay may be too high. None of the rest 
isolates positive by mouse bioassay was confirmed to be C. botulinum, so, no 
confirmation that mouse the bioassay is more sensitive than the MB-ELISA except in 
case of this one isolate.   
 
 
4.5 Discussion (general) 
Botulism is diagnosed by detecting BoNT and/or C. botulinum cells in the test 
sample. The sample may contain only detectable toxin or cells. So, diagnostics 
should include both toxin and cell detecting methods. In this study mouse bioassay, 
MB-ELISA and PCR were used to test for BoNTs or their genes of the isolates 
obtained by culture methods. Of 288 samples tested, only four isolates were 
confirmed (culture, bioassay, PCR and only three by immunoassay) to be C. 
botulinum and all from samples other than EGS samples. From this apparent final 
result, one may say that prevalence of C. botulinum in the test samples is extremely 
low, especially in GS samples, and the proposed linkage of EGS with C. botulinum is 
weakened. However, C. botulinum is deemed to be widely distributed in nature and 
may be normally present in the GI tract of horses (Ricketts and Greet, 1984), and 
hence expected to be found in both the disease and control samples (Szabo et al., 
1994b) with significantly more prevalence in the former. In addition, C. botulinum, its 
toxins, especially type C, and antibodies were detected in GS cases (Tocher et al., 
1923; Miller, 1994; Poxton et al., 1997; Hunter and Poxton, 1998; Poxton et al., 1998; 
Hunter et al., 1999; Hunter and Poxton, 2001; Garrett et al., 2002; Böhnel et al., 
2003; McCarthy et al., 2004b); however, isolation of the organism was reported only 
once (Tocher et al., 1923). C. botulinum isolation is known to be difficult (Smith and 
Sugiyama, 1988) due to its strict anaerobic character, high fastidiousness, needs 
good experience and special laboratory facilities, the bacteria can lose its toxicity 
during subcultures or before that, and above all, its isolation is specially difficult 
because of the inhibitory effect of other microflora (Graham, 1978; Szabo et al., 1994; 
Sandler et al., 1998; Böhnel and Lube, 2000). So, this negative result of isolation is 
not totally unexpected; and it may be more sound to relate the negative result found 
in this study to difficulty in isolating C. botulinum rather than its degree of prevalence 
in the samples tested. However, the C. botulinum isolates in the current study were 
from small number of botulism samples compared to the large number of GS 
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samples examined. Thus, one can say C. botulinum is at least not prevailing in these 
GS samples and its linkage with the disease remains doubtful. The neutralization 
results showed by some E. coli, C. perfringens-like and C. tetani isolates and their 
prevalence in GS cases samples and not in control samples may strongly suggest 
some association with the EGS either directly or indirectly. 
 
It is reported that the only reliable means of detecting, identifying, and typing BoNTs 
is the mouse bioassay (CDC, 1998). However, mouse bioassay was claimed to be 
not suitable for examination of test samples containing other lethal substances 
(Dezfulian and Bartlett, 1985). In the present study out of 53 neutralizations, only four 
were confirmed to be specific. Many of these non-specific results were confirmed to 
be due to cross-reactions with tetanus toxin and this can be avoided only by inclusion 
of antitetanus in the bioassay, especially in case of soil samples. Tetanus toxin was 
neutralized by different botulinum antitoxins (A-F) (Table 9), but mainly by polyvalent 
type ABE (AVENTIS BEHRING) and type CD mixture (Onderstepoort). Cross-reaction 
between TeNT and BoNTs is mainly expected to happen with type B (Dolimbeck et 
al., 2002); however, none of the isolates tested cross-reacted with type B antitoxin 
raised in chicken by IBT. So, specificity of the proteins of the toxoid and/or the animal 
species from which these antisera were obtained may have an effect. The toxin 
neutralization results shown by some E. coli and C. perfringens isolates (Table 6), 
which were investigated for contamination with C. tetani or C. botulinum, but not 
found, were strange. Such results were attributed to a non-isolatable level of 
contamination by C. tetani or C. botulinum or to some gene transfer which was then 
lost. 
   
The inhibitory effect of other microflora to C. botulinum was clearly demonstrated in 
the present work. None of the four confirmed C. botulinum isolates was isolated after 
enrichment in liquid medium. They were isolated either after direct heat or alcohol 
treatment or by direct streaking. The improper performance of heat or alcohol 
treatment also failed to demonstrate the bacterium. Furthermore, the author tried the 
isolation of C. botulinum from artificially contaminated samples. C. botulinum type A, 
B or C was added to liquid medium as a heavy inoculum together with other naturally 
contaminated faecal material and incubated for two and five days. Both types B and 
C were not recovered and the enrichment broth was negative by PCR, while type A 
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was recovered. The inhibition of C. botulinum by other microflora in vitro was similarly 
suspected to happen in vivo (Arnon et al., 1978; Bartlett, 1986) and hence types of 
organisms in the GI tract will determine if this animal is susceptible to C. botulinum 
infection or not.  
 
Among the confirmed C. botulinum isolates, one type D isolate was from the liver of a 
case of bovine botulism. Another isolate, dissimilar to C. botulinum, was isolated from 
the small intestine of the same animal which was positive for type D by the mouse 
bioassay and this result was attributed to contamination with C. botulinum. Botulism 
in this bovine case was diagnosed by the direct detection of the same toxin type 
during the routine diagnostic work in the institute. Also, from contents of small 
intestine of another bovine case, a lecithinase-positive clostridial isolate was positive 
for type CD in mice and type C by PCR; this was also attributed to low level of 
contamination by C. botulinum type C organisms (this was found possible due to non-
detectable swarming growth and character of C. botulinum demonstrated in this 
study). Again, the same toxin type was directly detected in the sample by the 
institute. These results may indicate that the bovine botulism in Germany could be 
mainly due to types D and C. This is in accordance with the findings of BÖHNEL 
(1999). Besides the classical form of botulism in cattle, a toxico-infectious form 
(visceral) was recently described (Böhnel et al., 2001). The isolation of confirmed two 
strains of C. botulinum type C from intestines of two broiler chickens from a farm with 
botulism outbreak may indicate that chicken botulism in this country is due to type C. 
Botulism in these two chicken cases was also confirmed by direct detection of the 
toxin by the institute. This result is in consistence with the fact that avian botulism 
worldwide is mainly due to type C (Graham and Smith, 1978; Smith and Sugiyama, 
1988). In addition to classical form of avian botulism, TI form was also reported in 
broiler chickens (Eklund et al., 1987, cited by Hunter and Poxton, 2002) due to high 
energy diet. Due to the increasing incidence of TI botulism and presence of different 
names for this form, one may classify botulism in humans and animals into two 
forms: 1) intoxication (the toxin produced ex vivo), which includes food-borne and 
inadvertent types; 2) toxico-infection (the toxin produced in vivo), which includes 
wound and visceral types (Böhnel et al., 2001); the visceral type includes the toxico-
infectious forms of young and adult humans and animals.  
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It was observed that the colonial morphology of the two type C isolates from broiler 
chickens and type D from a cow is different. The colony of one type C isolate is 
raised pyramidal with rhizoidal edge and the other one is flat or slightly raised with 
rhizoidal spreading edge; while that of type D is raised with uneven edge. So, these 
isolates may be different strains and because of their swarming character, which was 
not found reported, they may require further study to see if they were isolated before 
or not. 
 
The current study recommends the usage of Fastidious Anaerobic Agar (FAA) for 
isolation of C. botulinum and other clostridial species, especially C. perfringens and 
C. tetani.  
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5 SUMMARY 
Isolation and identification of Clostridium botulinum from field samples obtained from: 
i) equine grass sickness (EGS) cases (animal and environmental samples) together 
with control animal samples; and ii) classical botulism-suspected cases, was an 
objective. Using mouse bioassay, MB-ELISA and PCR to identify the isolates, out of 
288 samples investigated, only four isolates were confirmed to be C. botulinum and 
all from samples other than EGS samples. This result could show that C. botulinum is 
at least not prevailing in GS samples and its association with the disease remains 
doubtful. Two of the confirmed C. botulinum isolates were type C and the other two 
were type D. The two type C isolates were from intestinal contents of two broiler 
chickens from a farm with botulism outbreak; one of the type D isolates was from 
intestine of a case of bovine botulism and the other from faeces of a rabbit 
experimentally infected with C. botulinum type D together with other bacteria. The 
colonies of the two type C and the bovine type D isolate are not the same and the 
cells can swarm if the plates are not dry enough. So, these isolates may be different 
strains and because of their swarming character, which was not found reported, they 
may require further study to see if they were isolated before or not. 
 
Toxins of 53 isolates were neutralized by botulinum antitoxins by mouse bioassay, 27 
were from GS samples (24 from GS cases samples and three from control samples). 
The neutralized isolates were lipase-positive clostridia (23), lecithinase-positive 
clostridia (23) and E. coli isolates (7). Only four of them (from non-EGS samples) 
were confirmed to be specific. Ten of the lipase-positive isolates were from GS 
samples (all from case samples), ten of the lecithinase-positive isolates were from 
GS samples (nine from case samples and one from control samples) and all the 
seven E. coli isolates were from GS samples (five from case samples). Fourteen of 
the 53 isolates were found contaminated with C. tetani, which was proved to be the 
cause of their false-positive results. Tetanus toxin from several C. tetani isolates was 
neutralized by different botulinum antitoxins (A-F), but mainly by polyvalent type ABE 
(AVENTIS BEHRING) and type CD mixture (OVI). The neutralization results showed by 
E. coli, C. perfringens-like and C. tetani and the association of these species with the 
GS case samples and not with the control samples was considered to have a direct 
or indirect role in the aetiology of EGS. Also, it was observed that types and numbers 
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of some other Clostridium spp. are more prevalent in GS case samples than in 
control samples.  
 
The isolates with a positive result in the mouse bioassay were tested by PCR. Only 
six of them were positive by PCR, three type C and three type D. One type C and 
one type D isolate were lipase-negative and their result was not reproduced.  
 
The isolates tested by MB-ELISA were only 28, from those neutralized by type CD 
botulinum antitoxin mixture in the bioassay. Only three isolates had positive results, 
which were also positive by PCR. Two of them type C and one type D. MB-ELISA 
was specific, but less sensitive than other diagnostic means.  
 
The isolation and identification results showed that bovine botulism in Germany could 
be due to types D and C and avian botulism due to type C. 
 
The current study recommends the usage of Fastidious Anaerobic Agar medium for 
isolation of Clostridium species, including C. botulinum, C. perfringens and C. tetani. 
The inhibitory effect of other bacteria was confirmed by the finding that none of the 
four C. botulinum isolates in this study was obtained after enrichment in liquid 
medium; they were isolated either by direct plating, direct heat or alcohol treatment.  
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5 ZUSAMMENFASSUNG 
Das Ziel war die Isolierung und Identifizierung von Clostridium botulinum aus 
Feldproben von: i) Equine Grass Sickness (EGS)-Fällen (Tier- und Umweltproben) 
zusammen mit Kontrollproben von Tieren; und ii) Verdachtsfälle auf klassischen 
Botulismus. Mit Hilfe des Maus Bioassay, MB-ELISA und PCR wurden die Isolate 
identifiziert. Dabei konnten von 288 untersuchten Proben nur vier Isolate sicher als C. 
botulinum identifiziert werden, die alle nicht aus EGS-Proben stammten. Dieses 
Ergebnis konnte zeigen, daß C. botulinum zumindest nicht ausschlaggebend in GS-
Proben ist und seine Verbindung mit dieser Krankheit zweifelhaft bleibt. Zwei der vier 
bestätigten C.-botulinum-Isolate waren vom Typ C, die anderen beiden vom Typ D. 
Die beiden Typ-C-Isolate stammten aus dem Darminhalt zweier Masthähnchen eines 
Betriebes, auf dem Botulismus ausgebrochen war; eines der Typ D-Isolate war aus 
dem Darm eines Rindes mit Botulismus und das andere aus dem Kot eines 
experimentell mit C. botulinum Typ D und anderen Bakterien infizierten Kaninchens. 
Die Kolonien der zwei Typ-C-Isolate und des Typ-D-Isolates vom Rind sahen 
unterschiedlich aus und die Zellen können schwärmen, wenn die Agar-Platten nicht 
ausreichend trocken sind. Deshalb handelt es sich bei diesen Isolaten 
möglischerweise um unterschiedliche Stämme und wegen des schwärmenden 
Verhaltens, über das in der Literatur keine Angaben gefunden werden konnten, 
müssten sie weiter untersucht werden, um festzustellen, ob sie schon früher isoliert 
wurden.  
 
Toxine von 53 Isolaten wurden mit Botulinum-Antitoxinen im Mäuse-Bioassay 
neutralisiert. Davon waren 27 von GS-Proben (24 von GS-Fällen und 3 von 
Kontrollproben). Die neutralisierten Isolate waren Lipase-positive Clostridien (23), 
Lecithinase-positive Clostridien (23) und E. coli (7). Nur vier von diesen (keine Isolate 
der EGS-Proben) wurden sicher als C. botulinum identifiziert. Zehn der Lipase-
positiven Isolate waren von GS-Proben (alle von kranken Tieren), zehn der 
Lecithinase-positiven Isolate waren von GS-Proben (9 von kranken Tieren und eines 
von Kontrollproben) und alle sieben E. coli-Isolate von GS-Proben (5 von kranken 
Tieren). Vierzehn der 53 Isolate waren mit C. tetani kontaminiert, was als Ursache 
der falsch-positiven Ergebnisse nachgewiesen wurde. Tetanustoxin von 
verschiedenen C.-tetani-Isolaten wurde mit verschiedenen Botulinum-Antitoxinen (A-
F) neutralisiert, hauptsächlich jedoch mit polyvalenten Typ ABE (AVENTIS BEHRING) 
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und Typ CD-Mischungen (OVI). Die Ergebnisse der Neutralisationen von E. coli, C. 
perfringens-ähnlichen Bakterien und C. tetani sowie die Verbindung dieser Species 
mit Proben von GS-Fällen, jedoch nicht mit Kontrollproben, wurden als Hinweis auf 
eine direkte oder indirekte Rolle bei der Entstehung der EGS betrachtet. Ebenso 
wurde beobachtet, daß Typen und Anzahl einiger anderer Clostridium Species 
häufiger in GS-Proben als in Kontrollproben verkommen.  
 
Die Isolate, die im Mäuse-Bioassay positiv waren, wurden mit Hilfe der PCR 
untersucht. Nur sechs von diesen waren dabei positiv, drei waren Typ C und drei Typ 
D. Ein Typ C-Isolat und ein Typ D-Isolat waren Lipase-negativ; dieses Ergebnis var 
nicht reproduzierbar. 28 Isolate, die im Mäuse-Bioassay mit der Botulinum CD-
Antitoxin-Mischung neutralisiert wurden, wurden im MB-ELISA untersucht. Nur drei 
waren hier positiv dieselben, die auch in der PCR positiv waren. Von diesen waren 
zwei Typ C, eines Typ D. Der MB-ELISA war spezifisch, aber weniger sensitiv als 
andere Arten des Nachweises.  
 
Die Ergebnisse der Isolierung und Identifizierung zeigten, daß Botulismus bei 
Rindern in Deutschland durch die Typen C und D, bei Geflügel durch Typ C 
hervorgerufen werden kann.  
 
Die vorliegende Arbeit empfiehlt den Gebrauch von Fastidious Anaerobic Agar für die 
Isolierung von Clostridian, einschließlich C. botulinum, C. perfringens und C. tetani. 
Der hemmende Einfluß anderer Bakterien wurde dadurch bestätigt, dass keines der 
vier C.-botulinum-Isolate dieser Arbeit nach Anreicherung in flüssigem Medium 
nachgewiesen werden konnte; sie wurden nur entweder nach Ausstrich, Hitze- oder 
Alkoholbehandlung isoliert.          
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7 APPENDIX 
 
7.1 Media 
Fastidious Anaerobic Agar (FAA) (QUELAB, Montreal) (With some modifications) 
Formula (g/l): 
Peptone from meat     10.0  
Peptone from casein     10.0  
Yeast extract       3.0  
Glucose         1.0 
Starch                   1.0 
Sodium chloride       5.0 
Sodium pyruvate       1.0 
NaHCO3         0.4 
L-Arginine         1.0 
L-Alanine         1.0 
Cysteine HCl        0.5 
Trizma base         0.25 
Sodium succinate               0.5 
 Hemin         0.01 
 Vitamin K1        0.001 
Agar        14.0 
Horse blood or egg-yolk emulsion (50%)            25 ml 
 
Fastidious Anaerobic Broth (FAB) is the same as FAA above except that it is without 
agar and blood or egg yolk.  
 
Fortified FAB (fFAB) is FAB plus either EM pellets (0.5 g/5 ml), CM pellets (0.625 g/5 
ml) or BH granules (37.0 g/l).  
 
 
Reinforced Clostridial Medium (RCM) (MERCK) 
                                                                                        g/l 
Yeast extract       3.0  
Peptone from meat     10.0  
Meat extract                  10.0  
D-Glucose monohydrate      5.5 
Starch                   1.0 
Sodium chloride        5.0 
Sodium acetate       4.93 
L-Cysteine HCl        0.55 
Agar-agar         0.5 
 
Blood Agar (BA) is the same as RCM above, except that the agar is 15 g/l and plus 
5% (v/v) human blood.  
 
 
Cooked Meat (CM): (DIFCO, Detroit)  
  
CM pellets composition: 
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                                                                             g/l 
 Beef heart from 454 g     98.0  
 Proteose peptone      20.0     
 Dextrose        2.0  
 Sodium chloride       5.0  
 
Further enriched with: 
 L-Arginine        1.0  
 Hemin         0.01  
 Vitamin K1        0.001  
 L-Cysteine HCl        0.5 
 
0.625 g of CM pellets were added to 5 ml liquid medium. 
 
 
Cooked Meat Glucose Starch (CMGS) (Holdeman et al., 1977) 
 
 CM plus glucose (0.3%), starch (0.1%).  
 
 
Egg Meat (EM) (DIFCO) 
 
EM pellets composition per litre: 
 Beef muscle, from     454 g 
 Egg white, from     6 eggs 
 Calcium carbonate      5.0 g  
 
The following are further added to it: 
 Yeast extract     2.0 g 
 Ammonium sulphate     2.0 g 
 Glucose      2.0 g 
 L-Arginine      1.0 g 
 Haemin      0.01 g 
 Vitamin K1      0.001 g 
 
0.5 g EM pellets were added to 5 ml liquid medium. 
 
 
Brain Heart (BH) (MERCK) 
  
BH granules composition:  
g/l 
Extracts of brain and heart, and peptose 27.5  
D (+) Glucose      2.0  
Sodium chloride      5.0  
di-Sodium hydrogen phosphate    2.5  
 
37.0 g BH granules per 1l demineralised water. 
 
Further supplemented with: 
Yeast extract      5.0 
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L-Arginine       1.0  
 L-Cysteine HCl      0.5  
Haemin       0.01 
Vitamin K1         0.001   
 
 
Chopped Meat: (Holdeman et al., 1977) 
  
Ground beef (fat free)     500 g 
 Demineralised water      1000 ml 
 1 N NaOH        25 ml 
  
Fat and connective tissue have been removed from 500 g lean beef before grinding. 
Meat, water and NaOH are mixed and brought to boiling with stirring. Mixture is 
cooled down to RT and fat is skimmed off surface and filtered. To filtrate, sufficient 
water is added to make 1 litre. To this filtrate, trypticase (30 g), yeast extract (5 g), 
K2HPO4 (5 g) and resazurin solution (4 ml) are added. Then the mixture is boiled to 
dissolution and cooled. Then cysteine HCl (0.5 g), haemin (0.01g) and vitamin K1 
(0.001 g) are added. Meat particles are added to tubes containing 5 ml liquid medium 
(as 1 part to 4 parts fluid).  
 
7.2 Solutions and buffers 
Resazurin solution 
25 mg resazurin were dissolved in 100 ml demineralised water. Kept at 4 °C and 
discarded after 1 month.  
 
Hemin solution 
10 mg hemin were vortexed with 1 ml 1 N NaOH in a small plastic tube and added to 
1l medium.  
 
Vitamin K1 
10 µl vitamin K1 (MERCK) were dissolved into 1 ml 99% ethanol and used as 100 µl 
per litre of medium.  
 
Lysozyme solution 
10 mg lysozyme were dissolved into 10 ml demineralised water and filtered through 
0.45 µm filter. The solution added to the sterile liquid medium as 25 µl/5 ml. 
 
Gelatine phosphate buffer 
Solution A 
Gelatine    2% 
Na2HPO4 x 2 H2O   50 mM 
 
Solution B 
Gelatine    2% 
NaH2PO4 x H2O   50 mM 
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Solution A and B were mixed together, heated to dissolve gelatine and cooled at RT. 
The pH was adjusted to 6.2 and the solution sterilized at 121 °C for 15 min. 
 
Phosphate buffered saline  
NaCl     120 mM 
Na2HPO4 x 2 H2O     20 mM 
NaH2PO4 x H2O       6 mM 
pH 7.3 
 
Phosphate citrate buffer 
Solution A 
Na2HPO4 x 2 H2O   200 mM 
 
Solution B 
C6H8O7 x H2O   100 mM 
 
Solution A    25.7 ml 
Solution B    24.3 ml 
Demineralised water  50    ml 
pH 5.0 
 
 
7.3 Modified Gram stain (Hucker’s modification) 
 
Solutions 
1.  a.  20.0 g crystal violet 
 200 ml ethanol (96-99%) 
 
      b.  8 g ammonium oxalate 
           800 ml demineralised water 
 
2. 5 g iodine 
10 g KI 
1l demineralised water 
 
3. 200 ml acetone 
 250 ml ethanol  
 
5. 20 ml Ziel-Neelsen carbol fuchsin     
 180 ml demineralised water 
 
Method 
Air-dried and heat-fixed smears are stained by solution 1 (primary stain) for 30-90 s 
and then washed. Lugole’s iodine (solution 2) is added as a mordant for 60-120 s 
and then washed. Solution 3 is added as a decolourizing agent and the smear is 
washed. Then solutin 4 is added as a counter stain. The smear is washed, air-dried 
and examined under oil emmersion lens. Gram positive bacteria stain blue instead of 
violet (in case of non-modified stain) and the Gram negative bacteria stain red.  
 120
7.4 Colonies and Gram-stained smears of some important isolates in the study 
(colonies magnification is 40x and smears’ is 1000x) 
 
7.4.1 Swarming and discrete colonies and smears of the three confirmed C. 
botulinum isolates (Fig. 15a-c) 
 
 
 
 
 
 
 
 
 
Fig 15a: Colony and smear of one of the two type C isolates from intestines of  
two broiler chickens  
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Fig 15b: Colony and smear of one of the two type C isolates from intestines of  
two broiler chickens  
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Fig. 15c: Colony and smear of the type D isolate from bovine liver 
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7.4.2 Colonies and smears of some lipase-positive, lecithinase-positive, C. tetani  
and E. coli isolates from EGS samples which had positive neutralization 
results (Figs. 16-18) 
 
 
 
 
a. 
 
 
 
                                                                                   
 
b. 
 
 
Fig. 16a &b: Colonies and smears of some lipase-positive isolates from GS samples  
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c. 
 
 
      
 
 
d. 
 
Fig. 16c & d: Colonies and smears of some lipase-positive isolates from GS samples 
(cont.)  
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 b.                
                                    
 
                                                                          
 
 
 
 
Fig. 17a-c: Colonies and smears of some lecithinase-positive isolates from GS  
samples  
 
    
    a. 
    
 
     
      c.   
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Fig. 17d: Colonies and smears of some lecithinase-positive isolates from GS  
samples (cont.)  
 
 
                                                                                                                                                             
  
d. Smear from Gassner medium (aerobic)                      
 
Fig. 18a-d: Colonies and smears of E. coli  
 
b. Smear from FAA medium (anaerobic)    
c. Smear from BA medium (anaerobic) 
a.   Colony 
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              b. Swarming growth (thick film) 
      
             
 
 
 
 
 
 
 
 
 
 
 
 
                                                
                                     c. Discrete colonies (0.5 % PE-containing plates) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Fig. 19a-d: Colonies and smears of C. tetani  
 
a. Swarming growth (thin film) 
 
 
                              d. Gram-stained smears
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7.4.3 Colony and smear of C. perfringens isolate from bovine intestine which 
neutralized by two types of botulinum antitoxin type D and also type D by PCR 
 
 
 
Fig. 20: Colony and smear of C. perfringens isolate from bovine intestine  
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